JP2016029525A - Drug dosage information providing device and computer program for providing drug dosage information - Google Patents

Abstract

PROBLEM TO BE SOLVED: To administer an iron preparation and a red blood cell producing hormone with correlation in good balance to bring blood hemoglobin within a target range.SOLUTION: A drug dosage information providing processing includes: selecting red blood cell producing hormone dosage conversion tables 11 to 16 (Figs. 5 to 10) according to increase/decrease in the past dose of the red blood cell producing hormone (Fig. 11, steps 34 to 50); determining administration conditions A to G in the table from current data (first data) Hb1 and monthly variation data (first variation data) ΔHb; outputting information for decreasing the dose of the red blood cell producing hormone (administration conditions A and B, step 57), maintaining the current dose (administration conditions C to E, step 64), and increasing the dose (administration conditions F and G, step 77), as the monthly variation data ΔHb becomes larger in principle; and when decreasing the dose, if the administration of an iron preparation is decreased (step 60), correcting the information to the information for maintaining the current dose (step 61).SELECTED DRAWING: Figure 12

Description

  The present invention relates to a drug administration information providing apparatus and a computer program for providing drug administration information, and more particularly to an apparatus for providing information related to drug administration.

  In recent years, for the treatment of anemia and the like, administration of an iron agent or administration of an erythropoietic hormone agent has been performed. Administration of iron (iron deficiency anemia treatment) increases the number of red blood cells and compensates for hemoglobin.

  The erythropoiesis hormone is a hormone that promotes the production of red blood cells, and this administration increases the number of red blood cells in the blood and compensates for the amount of hemoglobin. However, these iron agents and erythropoietic hormone agents have been administered independently or without a clear correlation.

Japanese translation of PCT publication No. 2002-522558 Special table 2003-517462 gazette JP-T-2004-522696

  The present invention has been made to solve the above-described problems, and an object of the present invention is to provide a drug administration information providing apparatus capable of administering an iron agent and an erythropoiesis hormone agent in a well-balanced and correlated manner. That is. In patients undergoing dialysis, blood hemoglobin is low and it is not good to become anemic, but conversely, too much blood hemoglobin will interfere with artificial dialysis and adversely affect the blood. The target range of hemoglobin is lower than that of healthy people.

  In order to achieve the above object, the present invention provides a first capturing means for capturing the first data of blood hemoglobin of the patient, and the second data of the blood hemoglobin of the patient at a time prior to the capturing. A second capturing means for capturing, a first determining means for determining a first change amount data indicating a change amount of both of the captured data, and an iron preparation was administered to the patient at the time point related to the second data. A third capturing means for capturing information on whether or not, and a preset target range of hemoglobin in the blood in the patient, the first data is a low low value within the target range and the first change When the amount data is greater than or equal to the first predetermined value and the information taken in by the third taking-in means is information on administering iron to the patient, the patient's blood hemoglobin is increased. The first output means for outputting the information not to administer the iron agent to be administered, and at other times or when the first data is lower than the target range, the first output means for outputting information for administering the iron agent to the patient; When the information on the output means or the third intake means is information on administering the iron agent, information on reducing the dose of the erythropoietic hormone agent is output, and when the information is information on not administering the iron agent, erythrocyte production If the information of the first output means or the third uptake means is information for administering the iron agent, the dose of the erythropoietic hormone agent is changed. Outputs information that does not change and does not change, and if the information is information that does not administer the iron, outputs information that increases the dose of the erythropoietic hormone. And a blood cell production hormonal agent information output means.

  As a result, the blood hemoglobin does not inadvertently increase excessively, or the blood hemoglobin does not inadvertently decrease excessively, and the iron agent and the erythropoietic hormone agent can be administered in a well-balanced and correlated manner. In particular, even in patients who undergo artificial dialysis, iron agents and erythropoietic hormone agents can be administered in a well-balanced and correlated manner.

  An iron agent refers to a drug / supplement containing an iron component, and refers to a drug / supplement that has the effect of increasing hemoglobin in the blood of a patient by oral or intravenous injection (blood vessel injection). The erythropoietic hormone agent refers to a hormone agent or supplement that promotes the production of erythrocytes of a patient by oral or intravenous injection (vascular infusion), and includes erythropoietin, darbepoetin, epoetin alfa, epoetin beta, and epoetin beta begol.

1 shows an entire circuit of a drug administration information providing device and the like. The flowchart of a medicine administration information provision process (whole process) is shown. The flowchart of the said iron agent administration exclusion process (step 05) is shown. The flowchart of the said iron agent administration exclusion process (step 05) is shown. An erythropoietin preparation administration conversion table 11 in the program / data storage unit 7 is shown. An erythropoietin preparation administration conversion table 12 in the program / data storage unit 7 is shown. An erythropoietin preparation administration conversion table 13 in the program / data storage unit 7 is shown. An erythropoietin preparation administration conversion table 14 in the program / data storage unit 7 is shown. An erythropoietin preparation administration conversion table 15 in the program / data storage unit 7 is shown. An erythropoietin preparation administration conversion table 16 in the program / data storage unit 7 is shown. The flowchart of the administration information provision process (step 08) of the said erythropoietin formulation is shown. The flowchart of the determination process (step 32, 35, 38, 41, 44, 47, 50) of the administration conditions AG of the said erythropoietin formulation is shown. The flowchart of the determination process (step 32, 35, 38, 41, 44, 47, 50) of the administration conditions AG of the said erythropoietin formulation is shown.

DESCRIPTION OF SYMBOLS 1 ... Controller 2 ... Address / data bus line 3 ... Input part 4 ... Output part 5 ... Interface part 6 ... Information storage part 7 ... Program / data storage part 11, 12, 13, 14, 15, 16 ... Erythropoietin preparation administration conversion Table Hb ... Blood hemoglobin data Hb1 ... Current data (first data)
Hb2 ... 1 month ago data (second data)
Hb3 ... half a month ago data (third data)
ΔHb ... January change data (first change data) = Hb1-Hb2 (Hb2-Hb1)
δHb: Half-moon change data (second change data) = Hb1-Hb3 (Hb3-Hb1)
Target range (for iron agent): 10g / dl to 12g / dl
Target range (for erythropoietin formulation) ... 9g / dl to 12g / dl
Low value: 10 g / dl ≦ Hb <11 g / dl (10 g / dl to 11 g / dl)
Medium value: 11 g / dl ≦ Hb <11.5 g / dl (11 g / dl to 11.5 g / dl)
High value: 11.5 g / dl ≦ Hb <12 g / dl (11.5 g / dl to 12 g / dl)
First predetermined value A ... 0.6 g / dl
First predetermined value B ... 0.3 g / dl
Second predetermined value ...- 0.3 g / dl
Third predetermined value ...- 0.7 g / dl
Fourth predetermined value: the administration condition A or B of the erythropoietin preparation is selected. Each value of January change data (first change data) ΔHb or half-month change data (second change data) δHb Five predetermined values: respective values of January variation data (first variation data) ΔHb or half-month variation data (second variation data) δHb in which administration conditions C, D, or E of the erythropoietin preparation are selected Sixth predetermined value: respective values of January variation data (first variation data) ΔHb or half-month variation data (second variation data) δHb in which the administration condition F or G of the erythropoietin preparation is selected

(1) Overall Circuit FIG. 1 shows an overall circuit in a drug administration information providing apparatus, a data processing apparatus for providing drug administration information, an apparatus for realizing a drug administration information providing method, and drug administration information providing 1 shows an entire circuit of an apparatus for executing a computer program, a drug administration information providing apparatus, a server or a personal computer.

  This whole circuit is centered on a controller 1 (CPU, ROM, RAM, etc., which is a central processing unit), an input unit 3 via an address / data bus line 2 through which an address signal and a data signal are transmitted bidirectionally. The output unit 4, the interface unit 5, the information storage unit 6, the program / data storage unit 7 and the like are electrically connected.

  The input unit 3 includes a character input device such as a keyboard, a mouse, a touch panel, and a digitizer or an image input device. From the character input device, the patient's blood hemoglobin data, blood hemoglobin change data, iron administration information, erythropoietin preparation (erythropoietic hormone) dosage information, etc. are input, text numerical data, date and time Data and the like may be input, and further, commands for processing other various data, setting / instruction data, and other information may be input.

  The output unit 4 includes a display, a printer, and the like. The output unit 4 outputs various data such as the administration information of the drug, an input screen for various information, a control screen, an output screen, and the like on the display screen. Processing is performed.

  The interface unit 5 includes a LAN, a transmission / reception circuit for connecting an external device, and the like, and is connected to an external device including an external input device and an external output device. Through this interface unit 5, other hemoglobin data, blood hemoglobin change data, iron dosage information, erythropoietin dosage information, and other data, commands, etc., from other personal computers, etc. , Setting / instruction data, other information, and programs are sent and received.

  The program / data storage unit 7 (internal storage medium / means) includes a nonvolatile memory such as a flash memory, an EEPROM, an EPROM, and a CD-ROM, a RAM, a cache memory, a hard disk, a magnetic card, a magnetic disk, a CD-RAM, The storage device is roughly divided into two types of storage devices (storage means) such as a temporary storage memory using a DVD (digital video disk) or the like.

  The ROM of the program / data storage unit 7 stores programs executed by the drug administration information providing apparatus (overall circuit) and general-purpose data used for various processes. This program corresponds to the flowchart described later. Further, the temporary storage memory of the program / data storage unit 7 is used as temporary storage of data during program processing, that is, as a working memory or a cache memory, and stores flags, modes, and the like.

  The information storage unit 6 (external storage auxiliary medium / means, auxiliary storage medium) includes a magnetic disk, an optical disk, a flexible disk (propy disk), a magnetic drum, a magnetic tape, a memory card, a CD-RAM, a CD-ROM, It is composed of a mass information storage / storage medium such as a DVD and an information writing / reading device (drive device, interface circuit) to these media.

  In some cases, the drug administration information providing device is a dedicated device that performs a single process using a program stored in advance in the ROM of the information storage unit 6, and the program stored in the information storage unit 6 is appropriately stored. A general-purpose computer device that is called into the RAM of the program / data storage unit 7 and activated. In this case, the information storage unit 6 stores programs including basic software (operating software), system software, and application programs executed by the controller 1.

  Then, when the power supply of the drug administration information providing apparatus is turned on or when a new program is started, the information is read out from the information storage unit 6 and is temporarily stored in the RAM of the program / data storage unit 7. And executed by the controller 1. That is, a program executed by the medicine administration information providing device is stored in the information storage unit 6, read out appropriately, and taken in by the controller 1.

  In this case, when changing to a new program, the program itself stored in the information storage unit 6 is replaced, or the CD-ROM, magnetic disk, flexible magnetic disk, etc. in which the program is stored are replaced. (Installed / transferred).

  Further, in the case of a computer device that exclusively executes a program stored in the EPROM of the program / data storage unit 7, a CD-ROM, a magnetic disk, a flexible magnetic disk, etc. are similarly replaced (install / transfer). In response, the EPROM or the like is rewritten or the ROM itself is replaced.

  In some cases, the new replacement of the program is sent from an external device such as another computer connected via the interface unit 5 via the Internet line, telephone line, public line, or LAN line. In other words, a program executed by the computer device (overall circuit) is exchanged directly with the information storage unit 6 or exchanged with a program sent from an external device in Japan or abroad via a communication network such as the Internet. Or

  Therefore, in some cases, a program executed in the drug administration information providing device (overall circuit) is sent from an external device in Japan and abroad every time it is activated. In other words, the application program is not stored in the information storage unit 6 of the drug administration information providing device, and only the role of the terminal device that executes the program sent from an external device in Japan and abroad provides the drug administration information of the present invention. It is given to the device (overall circuit). Furthermore, a program and data processed by the program are sent together from external devices in and outside the country, and after the data processing is performed by the program, the result is sent back to the external device in and outside the country.

  The program executed by the computer device is a program by a general computer system in which an application program is executed based on a basic program such as an OS in some cases, and is a unified program including the OS. A dedicated computer system in which only one program is executed. Therefore, these unified programs are given from external devices in Japan and overseas, and only application programs, basic programs, or part of programs are sent from external devices in Japan and overseas and executed.

  In some cases, another operating system, a system program (OS), and other programs are stored in advance in the computer apparatus, and the program is executed together with these OS and other programs. When this program is installed in the apparatus (computer main body) and executed, the processing described in each claim of the claims (claims) or other invention effects at the end is performed together with another program or alone.・ Execute the function.

  In some cases, a part or all of this program is stored and executed in one or more other domestic or foreign devices other than this device, and a communication means is provided between this device and another device. Thus, data to be processed / data / program already processed are transmitted and received, and the present invention is executed as the entire apparatus and another apparatus. These communication means are Internet communication systems.

(2) Storage Data in Program / Data Storage Unit 7 The controller 1 or the program / data storage unit 7 stores target range data. This target range data shows the range of values of normal or appropriate blood hemoglobin data Hb of the patient, and in the iron administration, as shown in FIGS. 3 and 4, from 10 g / dl (gram / deciliter) to 12 g / dl. In the erythropoietin preparation (erythropoietic hormone agent) administration, the range is 9 g / dl (gram / deciliter) to 12 g / dl as shown in FIGS. Therefore, there are two types of target range data.

  Among the target range data 10 g / dl to 12 g / dl in “iron agent”, the low value is in the range of 10 g / dl ≦ Hb <11 g / dl, and the medium value is in the range of 11 g / dl ≦ Hb <11.5 g / dl. The high value is in the range of 11.5 g / dl ≦ Hb <12 g / dl, and these values are also stored.

  Among the target range data 9 g / dl to 12 g / dl in the “erythropoietin preparation”, the low value is in the range of 10 g / dl ≦ Hb <11 g / dl, and the medium value is 11 g / dl ≦ Hb <11.5 g / dl. The range is high and the high value is in the range of 11.5 g / dl ≦ Hb <12 g / dl, and these values are also stored.

  Further, the controller 1 or the program / data storage unit 7 stores current data (first data) Hb1, one month previous data (second data) Hb2, half month previous data (third data) Hb3, one month variation data ( First change data) ΔHb, half-month change data (second change data) δHb, iron dosage data, iron dosage data, erythropoietin dosage data, erythropoietin dosage data, increase / decrease in erythropoietin dosage Data, TSAT data, ferritin data, etc. are also stored for each patient.

  Current data (first data) Hb1 indicates the blood hemoglobin data (g / dl) of the patient on the current day or in the near future. One month ago data (second data) Hb2 is collected from the patient one month ago The blood hemoglobin data (g / dl) is shown, and the half-month previous data (third data) Hb3 is the blood hemoglobin data (g / dl) collected from the patient half a month ago.

  Hb means hemoglobin. The current data (first data) Hb1 is input / stored / accumulated for each examination of the patient, and as time elapses, a time-counting circuit (not shown) in the drug administration information providing device (overall circuit) The data before half a month (third data) Hb3, the data before one month (second data) Hb2, and so on are automatically set.

  January change amount data (first change amount data) ΔHb is a subtraction value obtained by subtracting one month previous data (second data) Hb2 from the current data (first data) Hb1, that is, the most recent one month. The amount of change in blood hemoglobin level is shown. The half-month variation data (second variation data) δHb is a subtraction value obtained by subtracting the half-month previous data (third data) Hb3 from the current data (first data) Hb1, that is, blood in the latest half-month. Indicates the amount of change in hemoglobin.

  Such a calculation for obtaining the January variation data (first variation data) ΔHb and the half-month variation data (second variation data) δHb is executed at any time or in a program according to a flowchart described later. Is done. The calculation result is written and stored in the program / data storage unit 7.

  The iron agent administration data indicates whether or not the iron agent has been administered every month, one month before, and so on. This iron drug administration data is input by the output processing in steps 06 and 07 in FIG. 2 described later, or by medical treatment / consultation to the patient such as a doctor / pharmacist, and is written and stored in the program / data storage unit 7. The The dose data of the iron preparation indicates the dose of the iron preparation for the current one month before, half a month before, and so on.

  The erythropoietin preparation administration data indicates whether or not the erythropoietin preparation was administered every month, one month before, and so on. The dose data of the erythropoietin preparation indicates the dose of the erythropoietin preparation at the present time, one month before, half a month before.

  The dose data of this erythropoietin preparation is input by the output processing of Steps 57, 61, 64, 67, 77, and 78 of FIGS. 12 to 13 described later, or by medical treatment / consultation to the patient such as a doctor / pharmacist. Are written and stored in the program / data storage unit 7. In this case, the amount of increase / decrease determined in accordance with the increase / decrease / no change increase / decrease data output in steps 57, 61, 64, 67, 77, 78 with respect to the previous dose of erythropoietin preparation Added / subtracted. The amount of increase / decrease in the erythropoietin preparation is determined in advance by consultation / consultation with a doctor / pharmacist.

  The increase / decrease data of erythropoietin dosage is as follows (increase, decrease, decrease, no change) None). The increase / decrease data of the dose of this erythropoietin preparation can be obtained by the output processing of steps 57, 61, 64, 67, 77, 78 in FIGS. It is input and written and stored in the program / data storage unit 7.

  The above TSAT data shows the iron saturation rate, that is, how much iron is bound to protein in the body, that is, how much room for supplemented iron to be bound in the body, and the amount of serum iron divided by TIBC data The TIBC data shows the ability of iron to bind to proteins in the body.

  The ferritin data indicates the amount of iron (blood volume) stored in the liver. Each of the data is actually based on the date data that is timed in the drug administration information providing device when the data is input to the drug administration information providing device for each patient by the operator. Stored in the program / data storage unit 7 for each year / month / day data and for each patient, based on the date / time data and the current date data, the current date, the previous month, the previous half month, the previous month Two and a half months ago, three months ago, three and a half months ago, four months ago and four and a half months ago.

(3) Drug Administration Information Providing Process FIG. 2 shows a flowchart of the drug administration information providing process (overall process).
The processing of FIG. 2 is started by power-on or predetermined processing of program execution. Initialization processing is first executed (step 00), error check of the information storage unit 6 and program / data storage unit 7, and other initialization. Is done.

  Next, when the patient's electronic medical record is opened, the current data (first data) Hb1 is input, or if there is a predetermined instruction operation (step 01), the current data (first data) stored in the program / data storage unit 7 ) One month previous data (second data) Hb2 is subtracted from Hb1 to obtain January variation data (first variation data) ΔHb (step 02).

  Also, the half-month change data (second change data) δHb is obtained by subtracting the half-month previous data (third data) Hb3 from the current data (first data) Hb1. Similarly, the change amount data of other January period, half-month period, 1.5 month period, February period, 2.5 month period, March period,... Are obtained and stored in the program / data storage unit 7. Written and stored (step 02).

  Therefore, the half-month previous data (third data) Hb3 is the time between the time point related to the current data (first data) Hb1 and the time point related to the one month previous data (second data) Hb2. Blood hemoglobin will be taken up. Between these two time points, it may be one week or three weeks instead of half a month.

  Data obtained in this way includes January data for each month (periodic blood collection) and half-month data for half a month (intermediate blood collection) performed between the blood collections for each month. The distinction between the January data (periodic blood collection) and the half-month data (intermediate blood collection) is determined by the date of the first blood collection, but may be reset and newly determined.

  When the TIBC data is 20% or less, the iron saturation rate is low (step 03), the ferritin data is 100 ng / ml (nanogram / milliliter) or less, and the iron content (blood volume) in the liver is small (step 04). ), If the iron drug administration exclusion criteria are not met (step 05), the iron drug administration information, for example, information for administering 40 mg of the iron drug once a week for one month (four weeks) is output to the output unit 4 (step 06). .

  Therefore, if it does not correspond to the iron drug administration exclusion criteria, if the TIBC data is 20% or less and the ferritin data is 100 ng / ml or less, the information on the iron drug to be administered unconditionally is output (step 06). As a result, if the iron saturation rate is low and the amount of stored iron in the liver (blood volume) is small, information on which an iron preparation should be administered is output.

  If the criteria / conditions of steps 03 to 05 are not satisfied, information on the postponement of the administration of the iron agent is output to the output unit 4 (step 07). Thereby, it is prevented that blood hemoglobin increases too much.

  Next, the administration information providing process of the erythropoietin preparation (erythropoietic hormone agent) is executed (step 08). Thus, the iron agent and the erythropoietin preparation can be administered in a well-balanced manner by the correlation processing in Steps 06, 07 and Step 08.

(4) Iron agent administration exclusion process (step 05)
3 and 4 show a flowchart of the iron drug administration exclusion process (step 05).
In this processing, the current data (first data) Hb1 of the blood hemoglobin is read out from the program / data storage unit 7, and this is the low value 10g / dl ≦ Hb <10.5g / dl in the target range data. (Steps 10 and 11), similarly, the January change amount data (first change amount data) ΔHb is read from the program / data storage unit 7 and taken in, and this is 0.6 g / dl (first predetermined value A) or more. (Step 12) Further, the iron administration data of one month before is read and taken in, and when this is information to be administered (Step 13), information on non-administration of the iron agent is output to the output unit 4 (Step 07).

  As a result, even if the current data (first data) Hb1 is low within the target range, the monthly change data (first change data) ΔHb is positive and large, and the iron preparation data of the previous month is administered. The iron hemoglobin is not administered and blood hemoglobin is prevented from increasing too much. When the criteria / conditions of Steps 10 to 13 are not satisfied, information on the administration of the iron agent is output (Step 06).

  The current data (first data) Hb1 for the target range 10 g / dl ≦ Hb <12 g / dl of hemoglobin in the blood in the patient set in advance by the processing in steps 10 to 13, 06, 07 is the target data The low value within the range is 10 g / dl ≦ Hb <10.5 g / dl, and the above-mentioned January change data (first change data) ΔHb is not less than the first predetermined value A plus +0.6 g / dl Furthermore, when the iron agent administration data is information on administering an iron agent to the patient, information on not administering an iron agent that increases blood hemoglobin in the patient is output. At other times or when the current data (first data) Hb1 is lower than the target range, information for administering the iron preparation to the patient is output at Hb <10 g / dl.

  Further, the current data (first data) Hb1 of blood hemoglobin is read from the program / data storage unit 7 and taken in, and this is the low value 10.5 g / dl ≦ Hb <11 g / dl in the target range data (step 16) Similarly, the January variation data (first variation data) ΔHb is read from the program / data storage unit 7 and taken in, and this is equal to or greater than 0.3 g / dl (first predetermined value B) (step 17). Further, the iron administration data for one month before is read and taken in, and when this is the information to be administered (step 13), the information on the postponement of administration of the iron agent is output to the output unit 4 (step 07).

  This 0.3 g / dl (first predetermined value B) is smaller than the above-mentioned 0.6 g / dl (first predetermined value A). As a result, even if the current data (first data) Hb1 is low within the target range, the monthly change data (first change data) ΔHb is positive and large, and the iron preparation data of the previous month is administered. The iron hemoglobin is not administered and blood hemoglobin is prevented from increasing too much.

  In this case, when the current data (first data) Hb1 becomes larger than the above steps 11 to 13, the monthly change data (first change data) ΔHb for determining the reference / condition for not administering the iron agent The condition value is lowered. When the criteria / conditions of Steps 16 to 17 and 13 are not satisfied, information on the administration of the iron agent is output (Step 06). Note that the processing in steps 11 to 12 and the processing in steps 16 to 17 may be combined and combined into one.

  The current data (first data) Hb1 is obtained for the target range of hemoglobin in the blood in the patient set in advance by the processing in steps 16 to 17, 13, 06, 07, 10 g / dl ≦ Hb <12 g / dl. The low low value within the target range is 10.5 g / dl ≦ Hb <11 g / dl, and the January change data (first change data) ΔHb is the first predetermined value B plus +0.3 g / dl. As described above, when the iron administration data is information on administering an iron preparation to the patient, information on not administering an iron preparation that increases blood hemoglobin of the patient is output. In other cases, information for administering the iron preparation to the patient is output.

  Further, the current data (first data) Hb1 of the blood hemoglobin is read out from the program / data storage unit 7, and this is the median value 11g / dl ≦ Hb <11.5g / dl in the target range data (step 20) Similarly, when the January change amount data (first change amount data) ΔHb is read from the program / data storage unit 7 and taken in, and is equal to or more than minus −0.3 g / dl (second predetermined value) (step 21). ), Information on the postponement of administration of the iron agent is output to the output unit 4 (step 07). The minus −0.3 g / dl (second predetermined value) is smaller than the above 0.3 g / dl (first predetermined value).

  As a result, regardless of whether or not the iron preparation is administered before January, even if the current data (first data) Hb1 is medium within the target range, the monthly variation data (first variation data) ΔHb is medium. The iron hemoglobin is not administered and blood hemoglobin is prevented from increasing too much. When the criteria / conditions of Steps 20 to 21 are not satisfied, information on the administration of the iron agent is output (Step 06). In this case, as in step 13, when the iron agent administration data of one month ago is information to be administered, information that does not postpone iron agent administration may be output (step 07).

  The current data (first data) Hb1 for the target range 10 g / dl ≦ Hb <12 g / dl of hemoglobin in the blood in the patient set in advance by the processing in steps 20 to 21, 06, 07 is the target A second value that is a medium value 11 g / dl ≦ Hb <11.5 g / dl that is not less than the low value in the range and that the January change amount data (first change amount data) ΔHb is smaller than the first predetermined value. When the predetermined value is minus −0.3 g / dl or more, information not to administer the iron agent that increases the blood hemoglobin of the patient is output. In other cases, information to administer the iron agent to the patient is output.

  Further, the blood hemoglobin current data (first data) Hb1 is read from the program / data storage unit 7 and taken in, and this is the high value 11.5 g / dl ≦ Hb <12 g / dl in the target range data (step 24). ), Similarly, the January change amount data (first change amount data) ΔHb is read from the program / data storage unit 7 and taken in, and when it is equal to or greater than minus −0.7 g / dl (third predetermined value) (step 25). Then, the information regarding the non-administration of the iron agent is output to the output unit 4 (step 07). The minus −0.7 g / dl (third predetermined value) is smaller than the −0.3 g / dl (second predetermined value).

  As a result, regardless of whether or not the iron preparation is administered before January, even if the current data (first data) Hb1 is high within the target range, the January variation data (first variation data) ΔHb increases above a certain value. If it is large, no iron is administered and blood hemoglobin is prevented from increasing too much. When the criteria / conditions of Steps 24 to 25 are not satisfied, information on the administration of the iron agent is output (Step 06). In this case, as in step 13, when the iron agent administration data of one month ago is information to be administered, information that does not postpone iron agent administration may be output (step 07).

  The current data (first data) Hb1 is set to the target value 10 g / dl ≦ Hb <12 g / dl in the blood hemoglobin in the patient set in advance by the processing in steps 24 to 25, 06, and 07. A third predetermined value that is 11.5 g / dl ≦ Hb <12 g / dl above the medium value within the range and the January change data (first change data) ΔHb is smaller than the second predetermined value. When the value is minus −0.7 g / dl or more, information not to administer the iron agent that increases the blood hemoglobin of the patient is output. In other cases, information to administer the iron agent to the patient is output.

  Further, the current data (first data) Hb1 of blood hemoglobin is read from the program / data storage unit 7 and taken in, and if this is the median value 12g / dl ≦ Hb in the target range data (step 28), the iron preparation Information on the postponement of administration is output to the output unit 4 (step 07).

  As a result, when the current data (first data) Hb1 is very high outside the target range, information that does not postpone the administration of the iron agent is output, and blood hemoglobin is prevented from excessively increasing. When the criterion of step 28 is not satisfied, information on the administration of the iron agent is output (step 06).

  In this case, similarly to step 13, when the iron administration data of one month ago is information to be administered, and similarly to steps 12, 17, 21, and 25, regardless of whether or not the iron preparation is administered one month before, When the monthly change amount data (first change amount data) ΔHb is equal to or greater than a predetermined value that is smaller than the minus −0.7 g / dl, information on the non-administration of the iron agent may be output (step 07).

  As a result of steps 28, 06, and 07, the current data (first data) Hb1 is within the target range for a preset target range of hemoglobin in the blood of the patient 10 g / dl ≦ Hb <12 g / dl. When the high value is 12 g / dl ≦ Hb, which is equal to or higher than the above medium value, information not to administer the iron agent that increases the blood hemoglobin of the patient is output, and otherwise, information to administer the iron agent to the patient is output. .

  Furthermore, when the current data (first data) Hb1 is less than 10 g / dl and is very low outside the target range, information on the administration of the iron agent is output to prevent blood hemoglobin from running short (step 10). . In this case, similarly to step 13, when the iron administration data of one month ago is information to be administered, and similarly to steps 12, 17, 21, and 25, regardless of whether or not the iron preparation is administered one month before, When the monthly change amount data (first change amount data) ΔHb is equal to or larger than a predetermined value greater than the above-mentioned 0.6 g / dl, information on the postponement of the iron agent may be output (step 07).

  Regardless of the value of the current data (first data) Hb1, when the administration condition A of the erythropoietin preparation described later is met (step 29), information on the postponement of iron administration is output to the output unit 4 ( Step 07).

  As a result, the blood hemoglobin was higher, or the monthly change data (first change data) ΔHb or the half-month change data (second change data) δHb was larger as the dose of the erythropoietin preparation was decreased. In some cases, information indicating that the iron agent is not sent off is output (step 07), and the blood hemoglobin is prevented from excessively increasing.

  This also allows the iron agent and erythropoietin preparation to be administered in a balanced manner with a correlation. When the criteria / conditions of step 29 are not satisfied, information on the administration of the iron agent is output (step 06).

  In this case, similarly to step 13, when the iron administration data of one month ago is information to be administered, and similarly to steps 12, 17, 21, and 25, regardless of whether or not the iron preparation is administered one month before, When the monthly change amount data (first change amount data) ΔHb is equal to or greater than a predetermined value that is smaller than the predetermined values, information indicating that the iron agent is not sent off may be output (step 07).

  If the erythropoietin preparation administration condition A is satisfied by the processing of steps 29, 06, and 07, information indicating that no iron agent for increasing blood hemoglobin in the patient is administered is output; otherwise, the iron agent is administered to the patient. Information is output. Such processing as step 29 may be executed within the processing of other steps 10, 11, 12, 13, 16, 17, 20, 21, 24, 25, 28, or other administrations. Conditions B, C, D, E, F, and G may be determined.

  As described above, in the determination of the administration / dosage of the iron preparation in Steps 06 and 07, the determination is made with reference to the dosage of the erythropoietin preparation in Step 29. Therefore, the iron preparation and the erythropoietin preparation are correlated with good balance. Can be administered.

  As described above, in the processing of Steps 10 to 29, the administration / dose amount of the iron preparation is increased as the blood hemoglobin Hb is decreased or the blood hemoglobin is increased or decreased.

  In Steps 28 and 29, if only one of the criteria / conditions is satisfied, information indicating that the iron agent is not sent off is output (Step 07). If both of these criteria / conditions are not satisfied, information on the administration of the iron agent is output (step 06). If only one of the criteria / conditions of steps 28 and 29 is satisfied, information on the administration of the iron agent is output (step 06). If both of these criteria / conditions are satisfied, the administration of the iron agent is deferred. The information may be changed so that information not to be output is output (step 07).

  The information that should be administered iron agent or the information that does not postpone administration of iron agent that is output in step 06 or step 07 is written and stored in the program / data storage unit 7 and is stored in the examination after one month or half a month. It is read out and used for the calculation of the monthly change data (first change data) ΔHb, the calculation of the half-month change data (second change data) δHb, and other processes as described above.

(5) Erythropoietin preparation administration conversion table 11, 12, 13, 14, 15, 16
5 to 10 show erythropoietin preparation administration conversion tables 11, 12, 13, 14, 15, 16 in the program / data storage unit 7. Using this erythropoietin preparation administration conversion table 11, 12, 13, 14, 15, 16, each value of the current data (first data) Hb1 and each of the monthly change data (first change data) ΔHb The administration conditions A, B, C, D, E, F, and G of the erythropoietin preparation are determined by the value or each value of the half-month variation data (second variation data) δHb.

  The target range data in this erythropoietin preparation is 9 g / dl to 12 g / dl as described in the above (2) data stored in the program / data storage unit 7.

  The fourth predetermined value is the monthly change data (first change data) ΔHb or the half-month change in which the administration conditions A or B of the erythropoietin preparation for reducing the dose is selected in FIGS. Each value of data (second variation data) δHb is shown.

  The fifth predetermined value is the monthly change data (first change data) in which the administration conditions C, D, or E of the erythropoietin preparation with no increase / decrease in the dose is not selected in FIGS. ) Indicates each value of ΔHb or half-month variation data (second variation data) δHb.

  The sixth predetermined value is the monthly change data (first change data) ΔHb or the half-month change in which the administration condition F or G of the erythropoietin preparation for increasing the dose in principle is selected in FIGS. Each value of data (second variation data) δHb is shown.

  Therefore, the values of the fourth predetermined value, the fifth predetermined value, and the sixth predetermined value individually change depending on the value of the current data (first data) Hb1 on the left edge of FIGS. In response to this change, individual change is also made depending on the value of January change data (first change data) ΔHb or half-month change data (second change data) δHb, and the erythropoietin preparation administration conversion table 11, It also changes every 12, 13, 14, 15, 16.

  The erythropoietin preparation conversion table 11 is selected and used when the erythropoietin preparation dosage does not change during the last three months. The erythropoietin preparation administration conversion table 12 is selected and used when the dosage of the erythropoietin preparation is increased or decreased half a month ago. The erythropoietin preparation conversion table 13 is selected and used when the dosage of the erythropoietin preparation is increased one month ago.

  The erythropoietin preparation administration conversion table 14 is selected and used when the dosage of the erythropoietin preparation is increased 1.5 to 3 months ago. The erythropoietin preparation conversion table 15 is selected and used when the dose of the erythropoietin preparation is reduced 1 to 3 months ago. The erythropoietin preparation conversion table 16 is selected and used regardless of the increase or decrease of the erythropoietin preparation during half-month intermediate blood collection.

  Therefore, when the dose of the erythropoietin preparation is increased (steps 40 → 41, 43 → 44 in FIG. 11 described later), the correction for increasing the fourth predetermined value, the fifth predetermined value, or the sixth predetermined value is performed. Is done. For example, in the table 13 in which the erythropoietin formulation in FIG. 7 is increased or decreased without changing the erythropoietin formulation in FIG. 5, in the table 13 in which the erythropoietin formulation is increased in FIG. 7, each value of the monthly variation data (first variation data) ΔHb is an exception. Although there are places where the same value is maintained, -1.9 → -1.4, 1.5 → 1.6, −1.1 → −0.9,..., 1.8 → 2. Corrections are made to increase from 0, -0.6 to -0.5, and so on.

  Further, when the dose of the erythropoietin preparation is reduced (step 49 → 50 in FIG. 11 described later), the fourth predetermined value, the fifth predetermined value, or the sixth predetermined value is corrected. For example, in the table 15 for reducing the erythropoietin formulation in FIG. 9 with respect to the table 11 with no increase / decrease in the erythropoietin formulation in FIG. 5, each value of the monthly variation data (first variation data) ΔHb is an exception. Although there are places where the same value is maintained, 1.3 → 1.1, −1.1 → −1.4, 1.5 → 1.3, 1.1 → 0.9, and so on. A fix to make it smaller.

  In this case, the administration conditions A and B to be reduced in principle are grouped together, the administration conditions C, D, and E that are not changed in principle are grouped together, and the administration conditions F and G to be increased in principle are grouped together. Therefore, the monthly change data (first change data) ΔHb and the half-month change data (second change data) at the boundaries between the administration conditions A and B, between the C and D and E, and between the F and G boundaries. ) ΔHb is excluded. May be included in some cases.

  When the dosage of the erythropoietin preparation is increased, all the fourth predetermined value, the fifth predetermined value or the sixth predetermined value are corrected to increase this value, and the erythropoietin preparation is converted. The value of January change amount data (first change amount data) ΔHb in the tables 11, 13, 14, and 15 may be changed.

  In addition, when the dose of the erythropoietin preparation is reduced, the fourth predetermined value, the fifth predetermined value, or the sixth predetermined value is corrected to reduce this value, and the erythropoietin preparation is converted. The value of January change amount data (first change amount data) ΔHb in the tables 11, 13, 14, and 15 may be changed.

  The conditions and criteria for selecting the administration conditions A, B, C, D, E, F, and G of the erythropoietin preparation are current data (first data) Hb1, January variation data (first variation data) ΔHb. , Changes depending on the half-moon change amount data (second change amount data) δHb, and also changes every erythropoietin preparation administration conversion table 11, 12, 13, 14, 15, 16.

  That is, the dose of the erythropoietin preparation decreases as the above-mentioned monthly change data (first change data) ΔHb or half-month change data (second change data) δHb increases, without increasing or decreasing without changing. Corrected in direction. Thereby, the administration conditions A, B, C, D, E, F and G of the erythropoietin preparation are also corrected.

  Further, the values of the fourth predetermined value, the fifth predetermined value, and the sixth predetermined value are corrected to be smaller as the current data (first data) Hb1 is larger, that is, the current data (first data) Hb1. The smaller the value, the larger the correction. Thereby, the administration conditions A, B, C, D, E, F and G of the erythropoietin preparation are also corrected.

  The erythropoietin formulation administration conversion tables 12 and 16 in FIGS. 6 and 10 are different from the erythropoietin formulation administration conversion tables 11 or 13, 14, and 15 in FIG. 5 in that the monthly variation data (first variation data) ΔHb is It is replaced with half-month variation data (second variation data) δHb.

  The fourth predetermined value, the fifth predetermined value, or the sixth predetermined value is set when the current data (first data) Hb1 is large, for example, when 12 ≦ Hb, 11.5 ≦ Hb,. , There are exceptions, but there are also places where the same value remains, but 0 → 0.6, 0.6 → 1.1, −1.9 → −1.4, −1.9 → −1.4 And so on, it ’s a big correction. Conversely, if the January change data (first change data) ΔHb is small, for example, if Hb <9, Hb <9.5,..., There are exceptions, but the same value remains. There are some cases, but it is corrected as small as 2.5 → 2, 1.8 → 1.5, 0.5 → 0, −0.2 → −0.5, 0.5 → 0, etc. .

  When the current data (first data) Hb1 is large, all of the fourth predetermined value, the fifth predetermined value, or the sixth predetermined value are corrected to increase this value, and the erythropoietin preparation is administered. The value of the half-month variation data (second variation data) δHb in the conversion tables 12 and 16 may be changed.

  In addition, when the current data (first data) Hb1 is small, all of the fourth predetermined value, the fifth predetermined value, or the sixth predetermined value are corrected to reduce this value, and the erythropoietin preparation is administered. The value of the half-month variation data (second variation data) δHb in the conversion tables 12 and 16 may be changed.

(6) Dosing information provision processing of erythropoietin preparation (step 08)
FIG. 11 shows a flowchart of the administration information providing process (step 08) of the erythropoietin preparation. Read the previous dose data of the erythropoietin preparation one month before or half a month and the dose data of the erythropoietin preparation half a month or one month before stored in the program / data storage unit 7, and the difference between the two data Is obtained, and the increase / decrease data of the dose of the erythropoietin preparation is obtained and captured (step 30).

  In the same way, other month, half-month, 1.5-month, February-month, 2.5-month, March-period, etc. data are calculated for every half-month or for every month. / Written and stored in the data storage unit 7 (step 31). In the administration of erythropoietin preparations, there is no distinction between January data (periodic blood collection) and half-month data (intermediate blood collection), but it may be present.

  If the current examination, that is, blood collection is half-month data (intermediate blood collection) (step 31), the current data (first data) Hb1 and half-month variation data (second variation data) δHb are stored from the program / data storage unit 7. Is read and the erythropoietin preparation administration conversion table 16 is used to determine the administration conditions A to G of the erythropoietin preparation (step 32).

  If this test, or blood collection, is January data (periodic blood collection) (step 31), if the erythropoietin preparation dose has not been increased or decreased in the last 3 months, that is, if there is no increase or decrease that does not change ( Step 34), the current data (first data) Hb1 and the monthly change data (first change data) ΔHb are read from the program / data storage unit 7, and the erythropoietin preparation administration conversion table 11 is used. The administration conditions A to G of the erythropoietin preparation are determined (step 35).

  Next, if the dose of the erythropoietin preparation over the three months read out and taken in is increased several times, it is determined whether the dose of the latest latest erythropoietin preparation is increased or decreased (step 36).

  In addition, the last increase / decrease in the last three months has increased (step 36), and if the dose of the erythropoietin preparation has been increased half a month before (step 37), the current data (first data) from the program / data storage unit 7 ) Hb1 and half-month variation data (second variation data) δHb are read out and the erythropoietin formulation administration conversion table 12 is used to determine the administration conditions A to G of the erythropoietin formulation (step 38).

  Furthermore, the last increase / decrease in the last three months has increased (step 36), and if the dose of the erythropoietin preparation has been increased one month before (step 40), the current data (first data from the program / data storage unit 7) Data) Hb1 and January change data (first change data) ΔHb are read out and the erythropoietin preparation conversion table 13 is used to determine the administration conditions A to G of the erythropoietin preparation (step 41). .

  If the last increase / decrease in the last three months has increased (step 36), and the dosage of the erythropoietin preparation has been increased from 1.5 months to 3 months ago (step 43), the program / data storage unit 7, the current data (first data) Hb1 and the monthly change data (first change data) ΔHb are read out, and the erythropoietin preparation administration conversion table 14 is used to determine the administration conditions A to G of the erythropoietin preparation. Determined (step 44).

  Furthermore, if the last increase / decrease in the last three months has decreased (step 36) and the dosage of the erythropoietin preparation has been reduced half a month before (step 46), the current data (first data) is stored from the program / data storage unit 7. ) Hb1 and half-month variation data (second variation data) δHb are read out and the erythropoietin formulation administration conversion table 12 is used to determine the administration conditions A to G of the erythropoietin formulation (step 47).

  If the last increase / decrease in the last three months has decreased (step 36) and the dose of the erythropoietin preparation has been decreased one to three months ago (step 49), the current data from the program / data storage unit 7 can be obtained. (First data) Hb1 and January variation data (first variation data) ΔHb are read, and the erythropoietin formulation administration conversion table 15 is used to determine administration conditions A to G of the erythropoietin formulation ( Step 50).

  When the dose of the erythropoietin preparation is changed a plurality of times in the above-described steps 34, 37, 40, 43, 46, and 49, this is used as a reference with reference to the latest change contents.

(7) Determination process of administration conditions A to G of erythropoietin preparation (steps 32, 35, 38, 41, 44, 47, 50)
12 to 13 show flowcharts of the determination process (steps 32, 35, 38, 41, 44, 47, and 50) of the administration conditions A to G of the erythropoietin preparation. In steps 32, 35, 38, 41, 44, 47, and 50, the erythropoietin preparation administration conversion tables 11, 12, 13, 14, 15, and 16 to be used are different, and strictly speaking, the flowchart / program is also different. Will be described with reference to typical examples.

  As a general rule, in the administration conditions A and B of the erythropoietin preparation, information for reducing the dosage of the erythropoietin preparation is output (steps 57 to 61), and in the administration conditions C, D, and E, there is no increase / decrease that does not change the dosage. Information is output (steps 64-73), and information for increasing the same dose is output under the same administration conditions F and G (steps 75-78).

  However, there is a change / modification / exception that does not change the dose when the information to reduce the dose is output (step 61), and there is no change information that does not change the dose. There are switching, correction, and exceptions that output information that increases the dosage when it is output (step 67), and information that does not change the dosage is output when information that increases the dosage is output There are switching, modification, and exceptions that are made (step 78).

(Administration condition A) In the above step steps 32, 35, 38, 41, 44, 47, and 50, any one of the erythropoietin preparation administration conversion tables 11, 12, 13, 14, 15, and 16 is selected as described above. Based on the read current data (first data) Hb1 and monthly change data (first change data) ΔHb or half-month change data (second change data) δHb, administration of the erythropoietin preparation Any of the conditions A, B, C, D, E, F, and G is selected (step 56).

  If the administration condition A is selected (step 56), information for reducing the dose of the erythropoietin preparation of this time is output (step 57). As described above, under the administration condition A, in principle, information for reducing the dose of the erythropoietin preparation is output in order to prevent the blood hemoglobin from being excessively increased (step 57).

(Administration condition B) If administration condition B is selected (step 56), the iron / dose administration data for the previous month and the previous month are read out and loaded from the program / data storage unit 7 (step 59). Of the three iron agent administration data, this time is information that no iron agent is administered (step 60), if it is information that is administered two months ago (step 62), or if it is information that is administered one month ago (step) 63) The information as it is without change is output without changing the dose of the erythropoietin preparation of this time (step 61).

  If it is information at this time that the iron preparation is administered (step 60), information for reducing the dose of the erythropoietin preparation is output (step 57). In addition, if the information is not administered in both the previous month and the previous month in steps 62 and 63 (steps 62 and 63), information for reducing the dose of the erythropoietin preparation is output (step 57).

  When information to reduce the dose of this erythropoietin preparation is output (steps 57 to 63), the current data (first data) Hb1 is information not to administer the iron agent, and the previous month data (second data) Hb2 is the iron agent. Information (step 60), that is, if the administration of the iron preparation has decreased over several months, there is a switching / correction / exception that outputs information indicating no change in the dose of the erythropoietin preparation (step 61). ).

  By the processes of Steps 56 to 63, the increase / decrease data of the dose of the erythropoietin preparation is not changed, and the above-mentioned January change data (first change data) ΔHb or half-month change data (second change data) If δHb is equal to or greater than the fourth predetermined value, information for reducing the dose of the erythropoietin preparation to the patient is output. This 4th predetermined value shows each value from which the administration conditions A or B of an erythropoietin formulation are selected in FIGS.

  In step 60, if the current information is about administering an iron preparation, the information of the current erythropoietin preparation may be outputted as it is without changing, or the information to be reduced may be outputted. Then, information to be increased may be output. Further, in the above step 60, if it is information not to administer the iron agent this time, the information that does not change the dose of the erythropoietin preparation of this time may be output as it is, or the information to be reduced may be output. Then, information to be increased may be output.

  Furthermore, if an iron preparation is administered one or two months before in steps 60 to 63, the information of increasing / decreasing without changing the dose of the current erythropoietin preparation may be output, or information to be increased May be output, or information to be reduced may be output. In addition, if the information is not administered in one month or two months in steps 60 to 63, the information may be output as it is without changing the dose of the erythropoietin preparation, or information to be increased. Information to be reduced may be output.

  When the iron preparation data at this time or one month before and two months before is the information on the administration of the iron preparation, the information for reducing the dose of the erythropoietin preparation is output by the processing of steps 59 to 63 described above. If the information is not to administer the iron, the information on the increase or decrease without changing the dosage of the erythropoietin preparation will be output, and the iron administration data of this time or one month before or two months ago will administer the iron In the case of information, information indicating no increase or decrease that does not change the dose of the erythropoietin preparation is output, and when the information is information that the iron preparation is not administered, information that increases the dose of the erythropoietin preparation is output.

  As described above, in the administration condition B, in principle, information for reducing the dose of the erythropoietin preparation is output in order to prevent the blood hemoglobin from being excessively increased (step 57). However, if the iron preparation is administered this time, blood hemoglobin may be further increased excessively, so the dose of the erythropoietin preparation is reduced (step 60 → 57).

  In addition, if no iron is administered at this time and iron is administered for at least one month out of the past two months, the increase in blood hemoglobin is thought to settle, so the decrease in the dose of erythropoietin preparation is postponed (step 60 → 62 → 61, 60 → 62 → 63 → 61). If no iron drug is administered for 3 months, the increase in blood hemoglobin is not due to iron drug administration, and the dose of the erythropoietin preparation is considered to be too large, so the dose of the erythropoietin preparation is reduced (steps 60 → 62 → 63 → 57).

(Administration condition C) Furthermore, if the administration condition C is selected (step 56), the information without change is output without changing the dose of the erythropoietin preparation of this time (step 64).

  As described above, under the administration condition C, since blood hemoglobin is in the target range in principle, information indicating no increase / decrease that does not change the dose of the erythropoietin preparation is output (step 64).

(Administration condition D) If the administration condition D is selected (step 56), the current iron drug administration data is read out from the program / data storage unit 7 (step 65), and this iron drug administration data is administered this time. (Step 66), the information without change is output without changing the dose of the erythropoietin preparation of this time (step 64).

  If the current iron administration data is information not to be administered this time (step 66), information for increasing the dose of the erythropoietin preparation is output (step 67).

  When information indicating no increase / decrease that does not change the dose of this erythropoietin preparation is output (steps 64 to 67), when the current data (first data) Hb1 is information that no iron preparation is administered (step 66), the erythropoietin preparation There are switching, correction, and exceptions that output information for increasing the dosage (step 67).

  As described above, in the administration condition D, since blood hemoglobin is in the target range in principle, information indicating no increase or decrease that does not change the dose of the erythropoietin preparation is output (step 64). However, if an iron preparation is not administered this time, it is better to raise blood hemoglobin with an erythropoietin preparation, so that the dosage of the erythropoietin preparation is increased (steps 66 → 67). If iron is administered this time, blood hemoglobin may increase in the future, so the increase in the dose of erythropoietin preparation is postponed (step 66 → 64).

(Administration condition E) Further, when the administration condition E is selected (step 56), the current iron preparation administration data is read out from the program / data storage unit 7 (step 69), and this iron preparation administration data is administered this time. If the information does not indicate (step 70), the information for increasing the dose of the erythropoietin preparation is output (step 67).

  If YES in step 70, that is, if the current iron administration data is information to be administered (step 70), the iron administration data of the previous month and the previous month is read from the program / data storage unit 7 and loaded ( Step 72) If these three iron administration data are all information to be administered, that is, if iron administration is performed for 3 consecutive months (Step 73), information for increasing the dose of the erythropoietin preparation is output. (Step 67).

  If NO in Step 73, that is, if any one of the three iron administration data is information that does not postpone administration (Step 73), information that does not change the dose of the erythropoietin preparation is unchanged. Output (step 64).

  When information indicating no increase / decrease that does not change the dose of the erythropoietin preparation is output (steps 69 to 73, 64, 67, 78), the current data (first data) Hb1 is the information for administering the iron agent. When the previous data (second data) Hb2 is also information for administering an iron preparation (steps 73 and 70), that is, when blood hemoglobin does not rise sufficiently by administration of an iron preparation, information for increasing the dose of an erythropoietin preparation is output. There are switching, correction, and exception (step 67).

  As a result of the processing in steps 56 and 64-73, the fifth variation data (first variation data) ΔHb or half-month variation data (second variation data) δHb is smaller than the fourth predetermined value. If it is greater than or equal to a predetermined value and less than the fourth predetermined value, the information is output as it is without increasing or decreasing without changing the dose of the erythropoietin preparation to the patient. This 5th predetermined value shows each value from which the administration conditions C, D, or E of an erythropoietin formulation is selected in FIGS.

  In the above-described steps 66, 70, and 73, if it is information to be administered this time, the information that does not change the dose of the erythropoietin preparation of this time may be output as it is, or the information to be reduced may be output. Alternatively, increasing information may be output. In Steps 66, 70, and 73, if the current information is not to be administered, the information that does not change the dose of the current erythropoietin preparation may be output as it is, or the information to be decreased may be output. Alternatively, increasing information may be output.

  Further, in the above-mentioned steps 66, 70, 73, if it is information to be administered one month before or two months ago, it may output the information as it is without increasing / decreasing without changing the dose of this erythropoietin preparation, Information to be reduced may be output, or information to be increased may be output. Further, in the above-mentioned steps 66, 70, 73, if it is information that is not administered one month before or two months ago, it may output the information as it is without changing the dosage of this erythropoietin preparation, Information to be reduced may be output, or information to be increased may be output.

  When the iron preparation data this time or one month before and two months before is the information on the administration of the iron preparation, the dosage of the erythropoietin preparation is determined by the processing of steps 65 to 66, 69 to 70, and 72 to 73. If the information to be reduced is output and the information is not to administer the iron, the information on the increase or decrease without changing the dose of the erythropoietin preparation will be output. When the data is information on the administration of the iron preparation, information indicating no increase or decrease in the dosage of the erythropoietin preparation is output, and when the information is information on not administering the iron preparation, information on increasing the dosage of the erythropoietin preparation is output. Will do.

  As described above, under the administration condition E, since blood hemoglobin is in the target range in principle, information indicating no increase or decrease that does not change the dose of the erythropoietin preparation is output (step 64). However, if the iron preparation is not administered this time, it is better to raise the blood hemoglobin with the erythropoietin preparation, so that the dosage of the erythropoietin preparation is increased (step 70 → 67). If blood hemoglobin does not increase even after administration of iron for 2 consecutive months, abandon the increase of blood hemoglobin with iron and aim to increase blood hemoglobin by increasing the dose of erythropoietin separately (step) 73 → 67).

(Administration condition F) Further, if the administration condition F is selected (step 56), the iron agent administration data for the previous month and the previous month are read out from the program / data storage unit 7 and fetched (step 75). Of these, if the information on the iron administration data is not administered 2 months ago and the information on the administration of iron administration data is not administered 1 month ago, but if the current iron administration data is information administered (step 76), this erythropoietin The information without change is output without changing the dosage of the preparation (step 78).

  If NO in step 76, that is, if the iron agent administration data two months ago or one month ago is information on administration of an iron agent, or if this iron agent administration data is information on not administering an iron agent (step 76) Then, information for increasing the dose of the erythropoietin preparation is output (step 77).

  When the information for increasing the dose of this erythropoietin preparation is output (steps 75 to 78), the current data (first data) Hb1 is the information for administering the iron preparation, and the previous month data (second data) Hb2 is the iron preparation. If there is information not to administer (step 76), that is, if the administration of the iron preparation has increased over several months, there is a change / modification / exception that outputs information indicating no change in the dose of the erythropoietin preparation (step 78). ).

  As described above, under the administration condition F, in principle, information for increasing the dose of the erythropoietin preparation is output in order to prevent blood hemoglobin from decreasing (step 77). However, if an iron preparation is administered for the first time in a long time without administering an iron preparation for the past two months, blood hemoglobin is expected to rise, so a decrease in the dose of the erythropoietin preparation is postponed (step 76 → 78). In other cases, since the blood hemoglobin is relatively low and there is a high possibility that the blood hemoglobin is further lowered or there is an inconvenience, the dosage of the erythropoietin preparation is increased (step 76 → 77).

(Administration condition G) If the administration condition G is selected (step 56), information for increasing the dose of the erythropoietin preparation is output (step 77).

  Through the processing of Steps 56 and 75 to 78, the sixth variation data (first variation data) ΔHb or the half-month variation data (second variation data) δHb is smaller than the fifth predetermined value. If it is not less than the predetermined value and less than the fifth predetermined value, information for increasing the dose of the erythropoietin preparation to the patient is output. This 6th predetermined value shows each value from which the administration conditions F or G of an erythropoietin formulation are selected in FIGS.

  Further, in the above step 76, if it is information to be administered this time, it may be output as it is without changing the dose of the current erythropoietin preparation, or information to be reduced may be output, Increasing information may be output. Furthermore, in the above step 76, if it is information not to be administered this time, it may be output as it is without changing the dosage of the erythropoietin preparation of this time, or information to be reduced may be output, Increasing information may be output.

  In step 76, if it is information to be administered one month before or two months ago, it may be output as it is without changing the dose of this erythropoietin preparation, or information to be increased is output. Alternatively, information to be reduced may be output. Further, in step 76, if the information is not to be administered one month before or two months ago, the information may be output as it is without changing the dose of the erythropoietin preparation, or the information to be increased is output. Alternatively, information to be reduced may be output.

  When the iron preparation data at this time or one month before and two months before is the information on the administration of the iron preparation, the information for reducing the dose of the erythropoietin preparation is output by the processing of steps 75 to 76. If the information is not to administer the iron, the information on the increase or decrease without changing the dosage of the erythropoietin preparation will be output, and the iron administration data of this time or one month before or two months ago will administer the iron In the case of information, information indicating no increase or decrease that does not change the dose of the erythropoietin preparation is output, and when the information is information that the iron preparation is not administered, information that increases the dose of the erythropoietin preparation is output.

  As described above, under the administration condition G, in principle, information for increasing the dose of the erythropoietin preparation is output in order to prevent blood hemoglobin from decreasing (step 77).

(Special administration conditions)
Although not shown in the flowcharts of FIGS. 12 to 13, the following processing is performed before the giving step 56. That is, when the dose of the erythropoietin preparation is increased three months ago and / or finally, the blood hemoglobin of this time is less than 10 g / dl, and the amount of change compared with the blood hemoglobin of three months ago is 0. In the case of 5 g / dl or less, information for increasing the dose of the erythropoietin preparation is output unconditionally.

  As a result, if blood hemoglobin does not increase so much even if the dose of the erythropoietin preparation is increased, the dose of the erythropoietin preparation is increased, and an improvement is made such that the blood hemoglobin increases.

  As described above, in determining the dose of the erythropoietin preparation in the above steps 57, 61, 64, 67, 77, 78, the dose of the iron agent is determined in the above steps 60, 62, 63, 66, 70, 73, 76. Since it is determined by reference, the iron agent and the erythropoietin preparation can be administered in a well-balanced and correlated manner.

  As described above, in the processing of steps 56 to 78, the dose of the erythropoietin preparation is increased as the blood hemoglobin Hb is decreased or the blood hemoglobin is increased or decreased. The dose of this erythropoietin formulation is corrected to decrease as the iron is administered (or several months ago).

  The process of referring to the dosage of iron in any one of the above steps 60, 62, 63, 66, 70, 73 or 76 is the same as the dosage of the erythropoietin formulation in the other steps 57, 61, 64, 67, 77 or 78. Any of the processes before the determination process may be executed.

(8) Replacement with other drugs Note that iron drugs include all drugs that have almost the same components as hemoglobin (iron) in blood, and erythropoietin preparations include all drugs that promote hematopoiesis that increase hemoglobin in the blood. , Darbepoetin, epoetin beta and the like. Darbepoetin is a trade name for erythropoietin preparations, and epoetin beta is also a trade name for erythropoietin preparations.

  Darbepoetin and epoetin beta are interchangeable, and darbepoetin 10 μg, 15 μg, 20 μg, 40 μg,..., 200 μg are replaced with epoetin beta 2250 IU, 3375 IU, 4500 IU, 9000 IU, ..., 45000 IU, respectively. Thus, other doses can also be proportionally converted or otherwise converted from these to determine the dose of the erythropoietin preparation.

  This conversion contrast is 1: 225, but is not limited to this ratio, depending on the iron saturation rate, the amount of iron in the liver (blood volume), or depending on the medical condition or even in the normal state, depending on the blood test results. Corrections may be added to the above ratio.

(9) Other Embodiments The present invention is not limited to the above-described embodiment, and various modifications can be made. For example, the drug administration information providing apparatus, the drug administration information providing method, and the computer program for providing drug administration information are executed by a device and a program that are provided in a plurality of locations, in a plurality of countries, and distributed in Japan and overseas. May be.

  The patient is assumed to be a dialysis patient, but may be a patient with iron deficiency anemia, other anemia, hypotension, other diseases / injuries, or a healthy person or a healthy person. The target range of blood hemoglobin may be the same as that in the iron preparation and that in the erythropoietin preparation, and may be wide in the iron preparation, and the upper limit or lower limit value may be smaller or larger than the other. Also good.

  The low value, medium value, and high value of the target range are not limited to those described above, and the classification of low value, medium value, and high value can be changed variously, and the upper limit value or lower limit value can be changed accordingly. The first predetermined value A, the first predetermined value B, the second predetermined value, the third predetermined value, the fourth predetermined value, the fifth predetermined value, and the sixth predetermined value are changed.

  Each of the low value, the medium value, and the high value may be further divided into multiple sections, and accordingly, the first predetermined value A, the first predetermined value B, the second predetermined value, and the third predetermined value The value, the fourth predetermined value, the fifth predetermined value, and the sixth predetermined value are further increased, and a predetermined value for classification is further increased between these predetermined values.

  One or more of the low value, the medium value, and the high value may be omitted, and the first predetermined value A, the first predetermined value B, the second predetermined value, and the third predetermined value may be omitted accordingly. One or more of the fourth predetermined value, the fifth predetermined value, and the sixth predetermined value are omitted.

  The period to be examined is every month, every half month, and depending on the examination content and administered drug, every several hours, every day, every day, every week, every week, every month, every half year, The above data may be input and taken in over a period of every year or every several years, and the process of the drug administration information providing apparatus may be executed.

  The numerical values determined in steps 03 and 04 may be other than those described above. For example, in the determination in step 03, whether the TSAT data is within a range of 25 to 30% or 30% or more may be used. Then, you may judge below arbitrary numerical values, such as between ferritin data 100-500 ng / ml, or between 10-1000 ng / ml, and the numerical value to judge is arbitrary.

  The dose of the above-mentioned iron preparation is 40 mg once a week for 4 weeks, but is not limited to this, and the iron preparation may be administered for each dialysis of the patient, or once a week for 3 weeks or less. It may be administered several times a week for a predetermined week, or the iron preparation may be administered for several months, for example, for 3 consecutive months.

  In the processing of steps 10 to 29 in FIGS. 3 and 4, the same table as the erythropoietin preparation administration conversion table 11, 12, 13, 14, 15, 16 may be used, and the current data (first data) Hb1, 1 More in accordance with the data before the month (second data) Hb2, the data before the half month (third data) Hb3, the amount of change in January (first change amount data) ΔHb, the amount of change in half moon (second change amount data) δHb Fine administration information of the iron agent may be determined and output.

  3 and 4, current data (first data) Hb1 or monthly change data (first change data) ΔHb, each numerical value of each section, erythropoietin preparation administration conversion table 11 of FIGS. 12, 13, 14, 15, 16 current data (first data) Hb1, January variation data (first variation data) ΔHb, half-month variation data (second variation data) δHb Numerical data, other current data (first data) Hb1, 1 month previous data (second data) Hb2, half month previous data (third data) Hb3, 1 month variation data (first variation data) ΔHb, half month variation Each numerical value of the amount data (second variation data) δHb can be changed, and various changes may be made depending on the subject of treatment depending on anemia, hypertension, hypertension, hypotension, etc. May be.

  The administration period of the erythropoietin preparation determined in steps 31, 34, 37, 40, 43, 46, and 49 in FIG. 11 can be variously changed, and is not limited to the period from half a month to March, but for several hours, one day, A period of several days, one week, several weeks, half a month, one month, several months, a half year, one year, several years may be covered.

  The information determined in steps 31, 34, 37, 40, 43, 46, and 49 of FIG. 11 is not only the increase / decrease / change change information of erythropoietin preparation, but also administration / dosage. Presence / absence information may be used. Similarly, the information output in steps 57, 61, 64, 67, 77, and 78 of FIGS. 12 and 13 is not only the increase / decrease / change change information of erythropoietin preparation, but also administration / administration. It may be information on whether or not there is, or may be a specific dose of erythropoietin preparation.

  Such a dose is determined in accordance with a medical examination / consultation by a doctor / pharmacist or the like, and is written and stored in the program / data storage unit 7. In this case, the amount of increase / decrease determined in accordance with the increase / decrease / no change increase / decrease data output in steps 57, 61, 64, 67, 77, 78 with respect to the previous dose of erythropoietin preparation Added / subtracted. The amount of increase / decrease in the erythropoietin preparation is determined in advance by consultation / consultation with a doctor / pharmacist.

  The information output at Steps 06 and 07 in FIG. 2 is not information on whether or not to administer an iron agent, but information on increase / decrease fluctuation of increasing / decreasing / not changing the dose of iron agent, or a specific iron agent May be administered. Such a dose is determined in accordance with a medical examination / consultation by a doctor / pharmacist or the like, and is written and stored in the program / data storage unit 7. The information taken and determined in steps 59, 60, 62, 63, 65, 66, 69, 70, 72, 73, 75, and 76 in FIGS. 12 and 13 is not information on whether or not to administer an iron agent. Increase / decrease fluctuation information of increasing / decreasing / not changing the iron dosage may be used.

  Step 29 in FIG. 4 is performed before Step 10, between Steps 10 and 11, between Steps 11 and 16, between Steps 16 and 20, between Steps 20 and 24, and between Steps 24 and 28. May be executed between. The administration conditions are not limited to the above A, B, C, D, E, F, and G, and may be increased or decreased.

  The conditions for selecting the administration conditions A, B, C, D, E, F, and G are selected according to the conditions of Steps 31, 34, 36, 46, 37, 40, 43, 46, and 49, but are not limited thereto. For example, if you reduce or increase the dosage of erythropoietin preparation 1 to 3 months before, if you reduce or increase the dosage of erythropoietin preparation 1 month before, reduce the dosage of erythropoietin preparation 1.5 to 3 months ago Alternatively, it may be replaced with an increase, or this case may be increased to FIG. 11, and the erythropoietin preparation administration conversion tables 11, 12, 13, 14, 15, 16 may be increased accordingly.

  Current data (first data) for selecting administration conditions A, B, C, D, E, F, and G in the erythropoietin preparation administration conversion tables 11, 12, 13, 14, 15, and 16 The range of Hb1 is 9 g / It may be higher or lower than dl to 12 g / dl.

  The erythropoietin preparation administration conversion tables 11, 12, 13, 14, 15, and 16 may be replaced with computer program flowcharts in the same manner as the processing of steps 10 to 29 in FIGS. Conditions A to G can be determined.

  Steps 00-08, 10, 11-13, 16-17 → 13, 20-21 → 06/07, 24-25 → 06/07, 28, 29, → 06, → 07, 30-50, → 32 , → 35, 37-38, 40-41, 43-44, 46-47, 49-50, 56-57, 56 → 59-63, 56 → 64, 56 → 65-67, 56 → 69-73, The order of each process of 56 → 75 to 78, 56 → 77 may be changed, a part or all of them may be omitted, and each step may be replaced with another equivalent process. , Change tables that exhibit equivalent functions, hardware or circuits can be partially or completely replaced, and the number of divided processes can be increased or decreased. Or two of these or One or more may be combined are combined or integrated.

  Controller 1, address / data bus line 2, input unit 3, output unit 4, interface unit 5, information storage unit 6, program / data storage unit 7, erythropoietin preparation administration conversion table 11, 12, 13, 14, 15, 16. The drug administration information providing device may be singular, plural, or three or more, some or all of each may be omitted, or the number may be increased or decreased by being divided and separated. In addition, the shape thereof can be arbitrarily changed, may be replaced with another equivalent, or two or more of these may be combined or integrated and used together.

  The execution of the administration information providing process (step 08) of the erythropoietin preparation may be selected by an operation of an operator (such as a doctor or a pharmacist). Further, the drug administration information providing process of Steps 00 to 07 may be executed after the administration information providing process of the erythropoietin preparation of Step 08, or the drug administration information providing process of Steps 00 to 07 and the erythropoietin preparation of Step 08. The administration information providing process may be selected and executed separately.

(10) Effects of other inventions [1] The first uptake processing for taking in the first data of blood hemoglobin of the patient, and the second data of the blood hemoglobin in the patient at a time before this uptake A second acquisition process, a first determination process for determining a first change amount data indicating a change amount of both of these acquired data, and whether the iron preparation was administered to the patient at the time point related to the second data. A third uptake process for taking in information on whether or not, and a preset target range of hemoglobin in the blood in the patient, the first data is a low low value within the target range and the first change amount When the data is greater than or equal to the first predetermined value and the information taken in the third taking-in process is information on administering iron to the patient, an iron agent that increases blood hemoglobin in the patient is added. A first output process for outputting information not to be administered, and otherwise outputting information for administering the iron preparation to the patient when the first data is lower than the target range, and the first output process Alternatively, when the information on the third uptake process is information on administering the iron agent, information on reducing the dose of the erythropoietic hormone agent is output, and when the information is information on not administering the iron agent, Outputs information that does not change the dosage and does not change, or if the information in the first output process or the third uptake process is information that administers the iron preparation, does not change the dosage of the erythropoietic hormone agent No information is output, and if the information is information that the iron preparation is not administered, the information for increasing the dose of the erythropoietic hormone agent is output. And emissions agent information output process, a computer program for providing drug administration information to be executed by a computer.

  By providing drug administration information to many patients, the ratio of deviation from the target range of hemoglobin in the blood is reduced, and the standard deviation / deviation value for the target range of hemoglobin in the blood is also reduced. The effect was obtained.

[2] First uptake means for taking in the first data of blood hemoglobin of the patient (current data Hb1), and second data of blood hemoglobin in the patient at the time before the uptake (one month before data) A second acquisition means for acquiring Hb2), a first determination means for determining first change amount data (monthly change amount data ΔHb) indicating a change amount of both of the acquired data, and the second data At such time, a third capturing means for capturing information on whether or not an iron preparation has been administered to the patient (iron preparation administration data) (step 13), and a target range (10 g) of hemoglobin in the blood in the preset patient / Dl to 12 g / dl), the first data is a low low value (10 g / dl ≦ Hb <11 g / dl) within the target range (steps 11 and 16) and the above The first change amount data is not less than the first predetermined value (A: 0.6 g / dl or B: 0.3 g / dl) (steps 12 and 17), and the information taken in by the third taking-in means. Is information to administer iron to the patient (step 13), information not to administer iron to increase blood hemoglobin in the patient is output (step 07). Otherwise, the first data is the target data. When the value is lower than the range (Hb <10 g / dl, step 10), information for administering the iron preparation to the patient is output (step 06). The first output means and the first output means or the third uptake When the information of the means is information for administering the iron agent (steps 60, 62, 63, 66, 70, 73, 76), information for reducing the dose of the erythropoietic hormone agent is output ( (Step 57) When the information is information that does not administer the iron agent (steps 60, 62, 63, 66, 70, 73, 76), information indicating no increase / decrease that does not change the dose of the erythropoietic hormone agent is output (step 57). Steps 61, 64, 78), or when the information of the first output means or the third intake means is information for administering the iron agent (Steps 60, 62, 63, 66, 70, 73, 76), Information on increase / decrease without changing the dose of the erythropoietic hormone agent is output (steps 61, 64, 78), and when the information is information that does not administer the iron agent (steps 60, 62, 63, 66, 70, 73). 76), which outputs information for increasing the dose of the erythropoietic hormone agent (steps 67 and 77), and an erythropoiesis hormone agent information output means. That drug administration information providing apparatus.

  As a result, when the hemoglobin in the blood is low in the target range, the iron agent is administered except when the blood hemoglobin change amount is high (increase), and only when the hemoglobin is high, the iron agent is not administered. The amount of hemoglobin inside can be kept within the target range so as not to decrease too much.

[3] The first uptake means, the second uptake means, the first obtaining means, and the third uptake means according to claim 2, comprising a preset target range of hemoglobin in the blood in the patient, The first data is a medium value (11 g / dl ≦ Hb <11.5 g / dl, step 20) that is equal to or higher than the low value within the target range, and the first change amount data is greater than the first predetermined value. When the value is not less than the second predetermined value (−0.3 g / dl) (step 21), information not to administer an iron agent that increases blood hemoglobin of the patient is output (step 07). Otherwise, the iron agent is output. Is output to the patient (step 06), and when the information of the second output means and the information of the second output means or the third take-up means is information for administering the iron preparation (step 60, 62, 63, 66, 70, 73, 76), and outputs information for reducing the dose of the erythropoietic hormone agent (step 57). When the information is information not to administer the iron agent (step 60, 62, 63, 66, 70, 73, 76), information on increase / decrease without changing the dose of the erythropoietic hormone agent is output (steps 61, 64, 78), or the second output means or the third When the information on the intake means is information for administering the iron agent (steps 60, 62, 63, 66, 70, 73, 76), information on increase / decrease without changing the dose of the erythropoietic hormone agent is output (step 61, 64, 78), when the information is information not to administer the iron agent (steps 60, 62, 63, 66, 70, 73, 76), the dose of the erythropoietic hormone agent 3. A drug administration information providing apparatus according to claim 2, further comprising: an erythropoiesis hormone information output means for outputting information for increasing the number of steps (steps 67 and 77).

  As a result, when the hemoglobin in the blood is in the middle of the target range, the iron agent is administered when the amount of change in blood hemoglobin is less than medium, and the iron agent is not administered only when the hemoglobin is in the middle or above. The amount of hemoglobin in the blood can be kept within the target range so that it does not decrease or increase too much.

[4] The first uptake means, the second uptake means, the first obtaining means, and the third uptake means according to claim 2, comprising a preset target range (10 g) of hemoglobin in blood in the preset patient / Dl to 12 g / dl), the first data is a high value (11.5 g / dl ≦ Hb <12 g / dl, step 24) within the target range, and the first change amount. When the data (January change data ΔHb) is equal to or greater than a third predetermined value (−0.7 g / dl) smaller than the second predetermined value (step 25) or higher than the target range (12 g / dl) ≦ Hb, step 28), information not to administer an iron agent that increases the blood hemoglobin of the patient is output (step 07). Otherwise, information to administer the iron agent to the patient is output (step 07). 06) When the information of the third output means and the information of the third output means or the third take-in means is information for administering the iron preparation (steps 60, 62, 63, 66, 70, 73, 76) When the information to reduce the dose of the erythropoietic hormone agent is output (step 57) and the information is information not to administer the iron agent (steps 60, 62, 63, 66, 70, 73, 76), the erythropoiesis hormone The information on the increase / decrease without changing the dose of the agent is output (steps 61, 64, 78), or when the information of the third output means or the third take-in means is the information for administering the iron agent (step 60, 62, 63, 66, 70, 73, 76), information on increase / decrease without changing the dose of the erythropoietic hormone agent is output (steps 61, 64, 78), and sympathy Is information not to administer the iron agent (steps 60, 62, 63, 66, 70, 73, 76), information to increase the dose of the erythropoietic hormone agent is output (steps 67, 77). 4. The drug administration information providing apparatus according to claim 3, further comprising an output unit.

  As a result, when the hemoglobin in the blood is high in the target range, the iron agent is administered only when the amount of hemoglobin change in the blood is low (decrease). The amount of hemoglobin can be kept within the target range so as not to decrease too much.

[5] The target range is a blood hemoglobin range of 12 g / dl (deciliter) to 10 g / dl, and the low value in the target range is 10 g / dl or more and less than 11 g / dl, The value is 11 g / dl or more and less than 11.5 g / dl, the high value within the target range is 11.5 g / dl or more and less than 12 g / dl, and the first predetermined value of the first variation data is plus +0 .6 g / dl or plus +0.3 g / dl, the second predetermined value of the first variation data is minus -0.3 g / dl, and the third predetermined value of the first variation data is minus -0. 5. The drug administration information providing apparatus according to claim 4, wherein the interval between the first data acquisition and the second data acquisition is one month. As a result, hemoglobin in the blood can be kept within the target range so as not to specifically decrease or increase.

[6] The first uptake means, the second uptake means, and the first obtaining means according to [2], wherein the dose of the erythropoietic hormone agent is around the time point related to the first data (current data Hb1). From the first obtaining means, the fourth fetching means for fetching information on whether there is no increase / decrease or increase / decrease that does not change, and no increase / decrease without changing the information from the fourth fetching means (steps 34, 35) If the first variation data (monthly variation data ΔHb) is equal to or greater than a fourth predetermined value (respective lower limit values for selecting the administration conditions A and B in Tables 11 to 16 in FIGS. 5 to 10), Information for reducing the dose of the erythropoietic hormone agent is output (step 57), and the first change data (monthly change data ΔHb) from the first obtaining means is a fifth value smaller than the fourth predetermined value. Predetermined value (FIGS. 5-1 If each of the lower limit values for selecting the administration conditions C to E in the tables 11 to 16 of 0) and less than the fourth predetermined value, information indicating whether the dosage of the erythropoietic hormone agent to the patient is not changed is not changed. Output (step 64), and the first change amount data (monthly change amount data ΔHb) from the first obtaining means is a sixth predetermined value smaller than the fifth predetermined value (table 11 in FIGS. 5 to 10). If it is greater than or equal to -16 administration conditions F and G, each lower limit value) and less than the fifth predetermined value, information for increasing the dose of the erythropoietic hormone to the patient is output (step 77); The fourth predetermined value, the fifth predetermined value, and the sixth predetermined value are corrected so as to be smaller as the value of the first data (current data Hb1) taken in from the first taking-in means is larger and output (see FIG. Although Hb1 became large at 5-10 mag The value of January change data ΔHb becomes smaller), or the smaller the value, the larger the value is corrected and output (the value of January change data ΔHb becomes larger as Hb1 becomes smaller in FIGS. 5 to 10 etc.) If the information from the output means and the fourth capturing means increases (steps 40 → 41, 43 → 44), the fourth predetermined value, the fifth predetermined value in the fourth output means, The sixth predetermined value is increased (for example, FIG. 5 does not change the erythropoietic hormone agent, no increase / decrease, Table 11 → the same increase in FIG. 7) In Table 13, ΔHb · δHb is changed from −1.9 → −1. (4, 1.5 → 1.6, −1.1 → −0.9,..., 1.8 → 2.0, −0.6 → −0.5, etc.) Information and the information from the fourth capturing means is reduced. (Step 49 → 50), correction is made to decrease the fourth predetermined value, the fifth predetermined value, or the sixth predetermined value in the fourth output means (for example, FIG. The table 11 is reduced in the same manner as in FIG. 9. In the table 15, ΔHb · δHb is 1.3 → 1.1, −1.1 → −1.4, 1.5 → 1.3, 1.1 → 0. 9. A drug administration information providing apparatus comprising a second correction means.

  As a result, the dose of erythropoietic hormone agent is decreased as the past dose of erythropoietic hormone agent is increased, and the dose is decreased as the dose of erythropoietic hormone agent is increased, or is decreased as the amount of hemoglobin in the blood is decreased. As the amount of change is larger, it is corrected in the direction of decreasing, and as it is smaller, it is corrected in the direction of increasing, so that the hemoglobin in the blood can be kept within the target range so as not to decrease too much.

[7] The third data (half month) of the blood hemoglobin of the patient between the time point related to the first data (current data Hb1) and the time point related to the second data (previous data Hb2) Fifth acquisition means for acquiring previous data Hb3), second determination means for determining second variation data (half-month variation data δHb) indicating the variation between the third data and the first data, The first change data (January change data ΔHb) in the fourth output means is replaced with the second change data (half-month change data δHb) obtained by the second obtaining means, and the fourth output is obtained. If the first data is large, the fourth predetermined value, the fifth predetermined value, or the sixth predetermined value in the means is greatly corrected (for example, 10, 12 ≦ Hb1, 11.5 ≦ Hb1, ... If larger, ΔHb · δHb is corrected to increase from 0 → 0.6, 0.6 → 1.1, −1.9 → −1.4, −1.9 → −1.4,. When the first data is small, it is corrected to be small (for example, in FIG. 5 to FIG. 6, when Hb1 <9, Hb1 <9.5,..., ΔHb / δHb is 2.5 → 2, 1 .8 → 1.5, 0.5 → 0, −0.2 → −0.5, 0.5 → 0,... 6. The drug administration information providing device according to 6.

  As a result, the dose of the erythropoietic hormone agent is reduced as the past dose of the erythropoiesis hormone agent is increased, and the dose is decreased as the dose is decreased, and the amount of hemoglobin in the blood is finer, for example, every half month than every month. It can be adjusted according to changes, and it can be within the target range so that hemoglobin in the blood does not decrease too much and does not increase too much.

[8] (Administration condition B) When the first output means and the third intake means of claim 2 are provided, and the information output by the fourth output means is information for reducing the dose of the erythropoietic hormone agent (Step 57) When the information output by the first output means is information not to administer the iron preparation and the information taken in by the third intake means is information to administer the iron preparation to the patient (Steps 60 and 62). 63) The information for reducing the dose of the erythropoietic hormone agent is switched to information that does not change and is not changed (step 61). The drug administration information according to claim 6, further comprising first switching means. Providing device.

  As a result, even if the dose of erythropoietic hormone agent is reduced, if the administration of iron agent is reduced, fine adjustment will not be made to reduce the dose of erythropoietic hormone agent, and the hemoglobin in the blood will not be reduced too much It can be within the target range.

[9] (Dose condition D) The first output means and the third take-in means of claim 2 are provided, and the information output by the fourth output means does not change the dose of the erythropoietic hormone agent. In the case of the above information (step 64), when the information output by the first output means is information that does not administer the iron agent to the patient (step 66), information that does not change the dose of the erythropoietic hormone agent is not changed. 7. The drug administration information providing device according to claim 6, further comprising second switching means for switching the information to increasing information (step 67).

  As a result, even if there is no increase or decrease without changing the dose of erythropoietic hormone, fine adjustment to increase the dose of erythropoiesis hormone is made if there is no or little iron administration, and hemoglobin in the blood is reduced too much It can be within the target range so as not to increase too much.

[10] (Administration condition E) The first output means and the third intake means according to claim 2 are provided, and the information output from the fourth output means does not change the dose of the erythropoietic hormone agent. (Step 64), when the information output by the first output means is information for administering an iron preparation and the information acquired by the third acquisition means is information for administering an iron preparation to a patient ( 7. A medicine according to claim 6, further comprising a third switching means (steps 67 and 73) for switching the information of no increase / decrease that does not change the dose of the erythropoietic hormone agent to the information to be increased (step 67). Administration information providing device.

  As a result, if the increase in hemoglobin and iron content is insufficient as a result of iron administration, fine adjustment to increase the dose of erythropoietic hormone agent is made so that the hemoglobin in the blood does not decrease too much and does not increase too much. Can be in.

[11] (Administration condition F) When the first output means and the third intake means of claim 2 are provided, and the information output by the fourth output means is information for increasing the dose of the erythropoietic hormone agent (Step 77), when the information output by the first output means is information for administering an iron preparation and the information acquired by the third acquisition means is information for not administering an iron preparation to a patient (Step 76), 7. The drug administration information providing apparatus according to claim 6, further comprising fourth switching means for switching the information for increasing the dose of the erythropoietic hormone agent to information that does not change and does not change (step 78).

  As a result, even if the dose of erythropoietic hormone agent is increased, if the administration of iron agent is increased, fine adjustment is made without changing the dose of erythropoiesis hormone agent, and hemoglobin in the blood is reduced too much. It can be within the target range so as not to increase too much.

(11) Development of anemia management algorithm for hemodialysis patients (the academic meaning of this drug administration information provision device)
(Various words)
The use of erythropoietin (ESA) and iron has made it possible to treat anemia in dialysis patients without transfusions, improving the quality of life of dialysis patients. Hemoglobin (Hb) in dialysis patients is said to have adverse effects on life prognosis, whether it is too high or too low, and the European version of the renal practice guidelines recommends management at Hb 10.0-12.0 g / dL. Similarly, the guideline of the Japanese Society for Dialysis Therapy recommends a target value of 10.0-11.0 g / dL for Hb, and 11.0-12.0 g / dL for relatively young patients with high activity. However, it has been reported that it is difficult to control Hb within a narrow range.

  So far, studies have been made to improve Hb control by creating an algorithm for managing anemia in dialysis patients, but there is no widely accepted algorithm. Many previous algorithms did not take into account red blood cell life, and only focused on the dose of ESA, and could not manage ESA and iron in a coordinated manner. In order to control Hb well, it is considered important to prevent the increase and decrease of unnecessary ESA by considering the lifespan of erythrocytes and managing ESA and iron preparation in cooperation. Moreover, it is considered necessary to prevent iron overdose by an algorithm. This time, we developed an algorithm that can implement these, and investigated how well Hb and iron indicators can be controlled.

(Method)
<Target>
Hemodialysis patients in the outpatient clinic at Yokkaichi Social Insurance Hospital (changed the hospital name to Yokkaichi Hazu Medical Center in April 2014, hereinafter referred to as Yokkaichi Social Insurance Hospital) were targeted. Of 88 total dialysis patients, 8 patients with chronic hepatitis, 8 patients whose primary physicians wanted to control anemia themselves, 7 inpatients, 4 patients who did not use ESA, patients using epoetin beta pegol Excluded were 4 patients, 2 patients with whom consent was not obtained, and 2 patients within 6 months of dialysis. As a result, a total of 53 persons were managed for anemia according to the anemia management algorithm described later from May 2013 to November 2013, and the effect was examined.

  As a discontinuation criterion during the study period, excluding cases where bleeding episodes with Hb 1.5 g / dL or more declined during the period, cases requiring blood transfusion, withdrawal from algorithms associated with transfer hospitals, death cases It was. This study was approved by the Ethics Committee of Yokkaichi Social Insurance Hospital, and written consent was obtained from the patients.

<Blood collection schedule>
Hb, iron, TIBC, and albumin were evaluated by regular blood sampling once a month, and an intermediate blood sample was set up to check Hb in the middle of each month. TSAT was calculated from iron and TIBC (TSAT = iron ÷ TIBC × 100). Ferritin was evaluated during regular blood sampling in May, August and November 2013. Both regular and intermediate blood collections were scheduled for dialysis at the beginning of the week (the day when the period was the longest since the last dialysis).

<Anemia management algorithm>
An anemia management algorithm was created with the goal of Hb falling in the range of 10.0 g / dL to 12.0 g / dL. Judgment based on the anemia management algorithm is always reflected in the treatment after being checked and approved by a doctor. The anemia management algorithm consists of an iron algorithm and an ESA algorithm.

<Iron algorithm>
TSAT and ferritin standards (Step 03, Step 04) followed the guidelines for the treatment of renal anemia in patients with chronic kidney disease of the Japanese Society for Dialysis Medicine. At the time of regular blood sampling, it was decided whether or not to administer iron. If the conditions were met, administration of iron 40 mg [Fedin IV (registered trademark) 40 mg, Nichi-Iko, Toyama City, Toyama Prefecture] I went for four weeks each time (this is one course). The determination of iron administration was not performed during the intermediate blood collection.

<ESA algorithm>
Any one of Tables 11 to 16 is used according to the past change status of ESA, and each condition (A to G) is divided according to the amount of change of Hb or Hb (ΔHb or δHb). If there have been multiple ESA changes in the last 3 months, the final change will be used as a reference (example: ESA increased 3 months ago and ESA decreased 2 months ago) In the case of ESA reduction 2 months ago).

  In addition, as a special condition to prevent Hb from prolonging at a low value, ESA was increased 3 months ago, but the current Hb is less than 10 g / dL. When the amount of change in the current Hb compared to the above is 0.5 g / dL or less, ESA was increased unconditionally.

<ESA stage>
The ESA stage was as follows.
Darbepoetin alfa (μg): 10, 20, 30, 40, 50, 60, 70, 80, 100, 120, 140, 160, 180
Epoetin beta (IU): 0, 750, 1500, 2250, 3000, 3750, 4500, 6000, 7500, 9000

  When changing the ESA amount, it was decided to increase or decrease one step at a time. Epoetin beta [EPO; Epogin (registered trademark), Chugai Pharmaceutical, Tokyo] and darbepoetin [DA; Nesp (registered trademark), Kyowa Hakko Kirin Co., Ltd., Tokyo] were used, and the conversion ratio was 225: 1. . For this reason, EPO 2250 unit and DA 10 μg, EPO 4500 unit and DA 20 μg, EPO 9000 unit and DA 40 μg are assumed to be equal to each other and can be converted into each other.

<Operation>
Due to the complexity of the algorithm, a program was created on Microsoft Excel (registered trademark) (Microsoft Corporation, Redmond, WA, US) that allows quick judgment according to the algorithm, and this program was used for actual operation.

<Statistical method>
Corresponding t-tests were used to compare Hb mean values and various patient background data. For comparison of the standard deviation of Hb, F test for two population variances when the observed values are correlated was used. Statistical calculation was performed using Microsoft Excel (registered trademark), and p <0.05 was considered significant.

(result)
There were 1 case of gastrointestinal bleeding with a decrease in Hb of 1.5 g / dL or more during the study period, 1 case requiring transfusion, and 2 cases of withdrawal from the algorithm accompanying transfer. Forty-nine cases were excluded. In addition, one of 49 patients refused monthly interim blood sampling, so anemia was controlled only by the results of regular blood sampling, but anemia management could be performed without any particular problems during the period.

  For this reason, Hb data at the time of periodic blood collection with data for 49 cases were used for analysis. Each blood sample was taken prior to dialysis at the beginning of the week, with the exception of one in May 2013, once in June 2013, one day before the previous dialysis and one day before dialysis. Blood was collected. However, no adverse effects were observed in the subsequent Hb control.

  There was no case where the judgment of the algorithm was rejected at the time of the doctor's check. During the period, the increase in ESA was 41 times, the decrease in ESA was 32 times, and the iron administration was performed 59 sets in total. A minimum of 0 mg and a maximum of 800 mg of iron were administered during the period, and the average iron dose during the period was 193 ± 179 mg.

  There was no significant difference in ESA dose before and after the introduction of the anemia management algorithm (p = 0.357), but ferritin decreased significantly (p = 0.011). The mean value of Hb was around 11.0 g / dL throughout, and no significant difference was observed before and after the introduction of the algorithm (p = 0.682). The achievement rate of Hb target (10.0 to 12.0 g / dL) was 77.6% before the introduction of the algorithm, but increased to 85.7% 4 to 6 months after the introduction of the algorithm. In addition, the standard deviation of Hb decreased after the introduction, and after 5 and 6 months of introduction, it decreased significantly compared to the introduction (p = 0.013, p = 0.047, respectively).

(Discussion)
The control of Hb and iron index has been improved by the introduction of anemia management algorithm in the following points. First, the achievement rate of Hb targets increased, and secondly, the standard deviation of Hb decreased significantly. The average value of Hb was around 11 g / dL and the standard deviation decreased, which is thought to have led to an increase in the target achievement rate. Thirdly, our algorithm reduced iron dosage and significantly reduced ferritin levels. These things can improve the prognosis of dialysis patients, and here are three reasons.

  First, leading many cases to the target range may lead to a better life prognosis. It is said that Hb in dialysis patients is too high or too low to have an adverse effect on life prognosis. According to a report from the Japanese Dialysis Medical Association, Hb 10-11 g / dL has the best 5-year survival rate. Although there was no significant difference for Hb 10-11 g / dL, the 5-year survival rate was the best at Hb 11-12 g / dL. From this, Hb 10-12 g / dL, which is within the target range of this time, is considered to be a reasonable range in terms of patient prognosis, and the fact that many cases could be led to this range is a better life prognosis. There was a possibility of connection.

  Second, a significant decrease in the standard deviation of Hb may lead to improved life prognosis. Pisoni and colleagues analyzed patient data from the Dialysis Outcomes And Practice Patterns Study (DOPPS) and patient data from the 2002 Medicare & Medicaid Services, and reported that the standard deviation of Hb was strongly positively correlated with dialysis patient mortality. doing. This suggests that a significant decrease in the standard deviation of Hb this time may improve life prognosis.

  Thirdly, suppressing iron dosage and significantly reducing ferritin levels may improve life prognosis. Kuo et al. Said that iron intake over 800 mg in 6 months increases cardiovascular events and mortality. In our algorithm, 960 mg of iron could be theoretically administered within 6 months, but there were no cases where the iron dose exceeded 800 mg within the current survey period. In our iron algorithm, the iron administration is controlled according to the Hb value and the amount of change, and it has a mechanism to limit the continuous administration of iron. May improve life prognosis.

  Hasuike et al. Followed 90 patients on dialysis for 107 months, with a high ferritin group (median 161.9 ng / mL) with ferritin of 100 ng / mL or higher and a low ferritin group with median ferritin of 100 ng / mL (median 37.0). ng / mL), it was reported that the mortality rate was significantly higher in the high ferritin group. The ferritin level of this low ferritin group is similar to that of our anemia management algorithm 6 months after the introduction of the anemia management algorithm, and controlling it to a low ferritin level may improve life prognosis.

  So far, studies have been conducted to improve Hb control by creating an algorithm for managing anemia in dialysis patients, but no algorithm has been widely accepted so far. Many of the other algorithms so far ignore red blood cell lifetimes and focus solely on ESA dose control without iron-ESA coordination.

  Kalicki and Uehlinger argue that the algorithm should consider at least all the information for the lifetime of red blood cells. Based on this, Lines et al. Have developed and reported an algorithm that predicts Hb change 90 days after changing ESA, taking into account red blood cell life. It is considered that it is not possible to cope with the change in Hb. On the other hand, there are some algorithms that take into account the iron index, but it seems that the cooperation between these ESAs and iron is weak and insufficient.

  Our algorithm succeeded in controlling Hb because we considered the lifespan of erythrocytes and managed the amount of ESA appropriately by managing ESA and iron in cooperation.

  In order to consider the lifespan of red blood cells, our algorithm adopts a mechanism that changes the sensitivity to changes in Hb for one month (ΔHb) and changes in Hb for half a month (δHb) according to recent changes in ESA. . As mentioned above, Kalicki and others argue that it will not work unless at least the information on the duration of the life of the red blood cell is taken into account when making the algorithm, because the life of the red blood cell is about 60 to 90 days A mechanism to change the sensitivity to the amount of change in Hb according to the change status of ESA in the last three months has been established.

  In addition, since differentiation into red blood cells takes time, it is said that it takes one week or more until the effect appears in Hb after changing the dose of ESA. For this reason, there is a possibility that the effect of increasing the amount will not be much after 1 month of ESA increase, and the algorithm after 1 month of ESA increase is distinguished from the algorithm after 1.5 to 3 months of ESA increase, and there is relatively little increase in Hb. Even if it is enough, it is set to wait without increasing ESA.

  The same thing can be considered one month after ESA dose reduction, but there are various factors other than ESA dose reduction in Hb, and the effect of delayed response of Hb to ESA dose reduction is considered negligible. It was. The algorithm 0.5 months after the increase / decrease in ESA was set to only correct large fluctuations in Hb as in the case of intermediate blood collection.

  Furthermore, in order to attach importance to the cooperation between ESA and iron, our algorithm adopted a mechanism to increase or decrease ESA after confirming the iron administration status. In general, Hb increases after iron administration, and Hb decreases when iron is insufficient. However, if such increase or decrease in Hb is mistakenly considered to be due to excessive or insufficient ESA, unnecessary ESA changes are introduced and stable Hb control thereafter. Cannot be expected. Therefore, in our algorithm, the increase / decrease in ESA was determined after confirming the iron administration status (conditions B, D, E, F). Details are shown below.

  First, Condition B has a mechanism to prevent unnecessary weight loss of ESA by checking the state of iron administration. Specifically, if the Hb level has increased after iron administration recently, the amount of ESA is considered not excessive and ESA is not reduced. The increase in Hb is expected after iron administration. According to Nakanishi et al., If 30-50 mg of iron is administered and used for erythropoiesis, Hb increases by 0.2-0.3 g / dL.

  Based on this, Hb may increase by about 0.6-1.6 g / dl after one course (160 mg) of our iron administration. Condition B is set approximately within this increase range, and it is possible to distinguish between an increase in Hb after iron administration and an increase in Hb that is thought to be due to an excess of ESA, and to prevent unnecessary ESA loss.

  Next, conditions D, E, and F are equipped with a mechanism to prevent unnecessary increase in ESA by checking the administration status of iron. Specifically, if Hb is low and recent iron supplementation is insufficient, ESA will not be increased if iron supplementation can be performed in the future. Conditions E and F are set to make it easier to make a decision to increase ESA than condition D, and the tendency is particularly strong in condition F.

  Under condition E, when iron was to be put in for 3 consecutive months, it was judged that the iron was not reacting so much, and ESA was increased. Under the condition F, the ESA was not changed only in the situation where the reaction to the iron was expected to start in the future without starting the iron for the past two months. In other cases, the ESA was increased. In this way, under conditions D, E, and F, Hb reduction, which is thought to be due to iron deficiency, and Hb reduction, which is thought to be due to ESA deficiency, can be distinguished according to the iron administration status, and unnecessary increase in ESA can be prevented.

(Conclusion)
In consideration of the life of erythrocytes, an anemia management algorithm has been introduced that can manage ESA dose appropriately by managing ESA and iron agent in cooperation, and can prevent excessive iron administration. As a result, the average value of Hb was stable near the median target, the achievement rate of Hb was increased, the Hb standard deviation was significantly decreased, and ferritin was significantly decreased. These can improve the prognosis of dialysis patients.

  Iron and erythropoietin are administered in a well-balanced manner and blood hemoglobin is kept within the target range. The erythropoietin formulation administration conversion tables 11 to 16 (Figs. 5 to 10) are selected according to the increase or decrease in the past dose of the erythropoietin formulation (steps 34 to 50 in FIG. 11), and the current data (first data) Hb1 is selected in this table. And the monthly change data (first change data) ΔHb or the half-month change data (second change data) δHb, the administration conditions A to G are determined. In principle, the January change data ΔHb or the half-month change data (Second change amount data) As δHb increases, the dose of the erythropoietin preparation decreases (dosage conditions A, B, step 57), does not change, does not increase or decrease (dosage conditions C to E, step 64), and increases (dosage conditions) F, G, Step 77) Information is output.

  Even when the dose of erythropoietin preparation is reduced, when the administration of iron is reduced (steps 60, 62, 63), it is corrected to the information of no increase / decrease not changed (step 61), and even when there is no increase / decrease not changed, When the effect of the iron preparation is insufficient (steps 70 and 73), it is corrected to information for increasing the dose of the erythropoietin preparation (step 67), and even when increasing the dosage of the iron preparation (step 76), The dose of the erythropoietin preparation is corrected so as not to increase or decrease (step 78).

Claims (11)

A first uptake process for taking up the first data of blood hemoglobin of the patient;
A second uptake process for taking up second data of blood hemoglobin of the patient at a time prior to this uptake;
A first obtaining process for obtaining first change amount data indicating a change amount of both of these captured data;
At the time of the second data, a third uptake process for taking in information on whether or not an iron preparation has been administered to the patient;
For the target range of hemoglobin in blood in the patient set in advance, the first data is a low low value within the target range, and the first variation data is not less than a first predetermined value, and When the information taken in the third uptake process is information that administers an iron preparation to the patient, information that does not administer an iron preparation that increases the blood hemoglobin of the patient is output, otherwise or the first data is When lower than the target range, a first output process for outputting information for administering the iron preparation to the patient;
When the information of the first output process or the third uptake process is information for administering the iron agent, information for reducing the dose of the erythropoietic hormone agent is output, and when the information is information for not administering the iron agent , Output the information on the increase or decrease without changing the dose of the erythropoietic hormone agent, or when the information on the first output processing or the third uptake processing is the information on the administration of the iron agent, If the information is information on not increasing or decreasing the dosage, and the information is not administering the iron preparation, the information on the erythropoietic hormone information is output to the computer. A computer program for providing drug administration information to be executed. A first capturing means for capturing first data of blood hemoglobin of the patient;
A second capture means for capturing second data of blood hemoglobin of the patient at a time prior to the capture;
A first obtaining means for obtaining first change amount data indicating a change amount of both of the captured data;
A third capturing means for capturing information on whether or not an iron preparation has been administered to the patient at the time of the second data;
For the target range of hemoglobin in blood in the patient set in advance, the first data is a low low value within the target range, and the first variation data is not less than a first predetermined value, and When the information captured by the third capturing means is information for administering an iron preparation to the patient, information indicating that no iron preparation for increasing blood hemoglobin in the patient is administered is output. Otherwise, or the first data is When lower than the target range, a first output means for outputting information for administering the iron preparation to the patient;
When the information of the first output means or the third uptake means is information for administering the iron agent, information for reducing the dose of the erythropoietic hormone agent is output, and when the information is information for not administering the iron agent When the information of the first output means or the third uptake means is information on administration of the iron agent, the information of the erythropoietic hormone agent is output. It was provided with erythropoietic hormone agent information output means for outputting information on increase / decrease without changing the dosage, and when the information is information not to administer the iron agent, the information for increasing the dosage of erythropoietic hormone agent is output. A drug administration information providing device characterized by the above. The first taking-in means according to claim 2, the second taking-in means, the first obtaining means, the third taking-in means,
For the target range of hemoglobin in the blood in the patient set in advance, the first data is a medium value equal to or higher than the low value within the target range, and the first change amount data is greater than the first predetermined value. A second output means for outputting information not to administer an iron agent that increases blood hemoglobin of the patient when the second predetermined value is not less than the second small value, and to output information for administering the iron agent to the patient otherwise ,
When the information of the second output means or the third intake means is information for administering the iron agent, information for reducing the dose of the erythropoietic hormone agent is output, and when the information is information for not administering the iron agent When the information of the second output means or the third uptake means is information on administration of the iron agent, the information of the erythropoietic hormone agent is output. It was provided with erythropoietic hormone agent information output means for outputting information on increase / decrease without changing the dosage, and when the information is information not to administer the iron agent, the information for increasing the dosage of erythropoietic hormone agent is output. The drug administration information providing device according to claim 2. The first taking-in means according to claim 2, the second taking-in means, the first obtaining means, the third taking-in means,
For the target range of hemoglobin in the blood in the patient set in advance, the first data is a high value that is not less than the intermediate value within the target range, and the first change amount data is greater than the second predetermined value. When the value is smaller than the third predetermined value or higher than the target range, information not to administer the iron agent that increases the patient's blood hemoglobin is output. Otherwise, information to administer the iron agent to the patient is output. And a third output means
When the information of the third output means or the third intake means is information for administering the iron agent, information for reducing the dose of the erythropoietic hormone agent is output, and when the information is information for not administering the iron agent When the information of the third output means or the third uptake means is information on administration of the iron agent, the information of the erythropoietic hormone agent is output. It was provided with erythropoietic hormone agent information output means for outputting information on increase / decrease without changing the dosage, and when the information is information not to administer the iron agent, the information for increasing the dosage of erythropoietic hormone agent is output. The drug administration information providing device according to claim 3. The target range is a blood hemoglobin range of 12 g / dl (deciliter) to 10 g / dl,
The low value in the target range is 10 g / dl or more and less than 11 g / dl, the medium value in the target range is 11 g / dl or more and less than 11.5 g / dl, and the high value in the target range is 11.5 g / dl. And less than 12 g / dl,
The first predetermined value of the first variation data is plus +0.6 g / dl or plus +0.3 g / dl, the second predetermined value of the first variation data is minus -0.3 g / dl, The third predetermined value of the variation data is minus −0.7 g / dl,
5. The drug administration information providing apparatus according to claim 4, wherein an interval time between the first data acquisition and the second data acquisition is one month. The first taking-in means according to claim 2, the second taking-in means, the first obtaining means,
In the vicinity of the time point related to the first data, a fourth capturing means for capturing information on whether the dosage of the erythropoietic hormone agent is increased or decreased or not changed, and
If the first change data from the first obtaining means is not less than the fourth predetermined value without any increase or decrease that does not change the information from the fourth uptake means, the dose of the erythropoietic hormone agent to the patient If the first change amount data from the first obtaining means is greater than or equal to a fifth predetermined value smaller than the fourth predetermined value and less than the fourth predetermined value, to the patient The information on the increase or decrease without changing the dose of the erythropoietic hormone agent is output, and the first change data from the first determining means is not less than a sixth predetermined value smaller than the fifth predetermined value and the If it is less than the fifth predetermined value, information for increasing the dose of the erythropoietic hormone agent to the patient is output, and the fourth predetermined value, the fifth predetermined value, and the sixth predetermined value are The value of the first data fetched from one fetching means is large A fourth output means for outputting the modified throat small, or small enough to largely corrected output,
If the information from the fourth capturing means is increased, the first correction is performed to increase the fourth predetermined value, the fifth predetermined value, or the sixth predetermined value in the fourth output means. Means,
If the information from the fourth capture means is reduced information, the second correction for correcting to reduce the fourth predetermined value, the fifth predetermined value, or the sixth predetermined value in the fourth output means And a drug administration information providing device. A fifth taking-in means for taking in the third data of blood hemoglobin of the patient at a time between the time point related to the first data and the time point related to the second data;
A second obtaining means for obtaining second change amount data indicating a change amount between the third data and the first data;
The first change amount data in the fourth output means is replaced with the second change amount data obtained in the second obtaining means, and the fourth predetermined value, the fifth predetermined value in the fourth output means, or The sixth predetermined value is provided with a third correction means for correcting the sixth predetermined value largely when the first data is large, and correcting the sixth predetermined value small when the first data is small. The medicine administration information providing device according to the description. The first output means according to claim 2 and a third take-in means,
If the information output by the fourth output means is information for reducing the dose of the erythropoietic hormone agent, the information output by the first output means is information that does not administer the iron agent, and the third intake means When the information taken in is information for administering an iron preparation to a patient, a first switching means is provided for switching the dose of this erythropoietic hormone agent to information that does not change and does not change the information to be reduced. The drug administration information providing device according to claim 6. The first output means according to claim 2 and a third take-in means,
When the information output by the fourth output means is information that does not change the dose of the erythropoietic hormone agent, the information output by the first output means is information that does not administer the iron agent to the patient. 7. The drug administration information providing device according to claim 6, further comprising a second switching means for switching the information of no increase / decrease that does not change the dose of the erythropoietic hormone agent to the information to be increased. The first output means according to claim 2 and a third take-in means,
When the information output by the fourth output means is information that does not increase or decrease the dosage of the erythropoietic hormone agent, the information output by the first output means is information for administering the iron agent, When the information captured by the third capturing means is information for administering an iron preparation to a patient, a third switching means is provided for switching the information that does not change the dosage of the erythropoietic hormone agent to the increasing information. The drug administration information providing device according to claim 6. The first output means according to claim 2 and a third take-in means,
When the information output by the fourth output means is information for increasing the dose of the erythropoietic hormone agent, the information output by the first output means is information for administering the iron agent, and the third intake means When the information taken in is information not to administer the iron preparation to the patient, a fourth switching means is provided for switching the information for increasing the dose of the erythropoietic hormone agent to information that does not change and does not change. The drug administration information providing device according to claim 6.

Images